var title_f6_31_6640="Corneal perferation in steroid-treated HSV keratitis";
var content_f6_31_6640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal perforation in steroid-treated herpes simplex (HSV) stromal keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6640=[""].join("\n");
var outline_f6_31_6640=null;
var title_f6_31_6641="Delapril: International drug information";
var content_f6_31_6641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"25\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Delapril: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adecut (JP);",
"     </li>",
"     <li>",
"      Delaket (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Delapril Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 15-30 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 15 mg, 30 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10362 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6641=[""].join("\n");
var outline_f6_31_6641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323556\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978439\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978441\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978444\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978440\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821232\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978443\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10362|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6642="Patient information: Atrial septal defect (The Basics)";
var content_f6_31_6642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83027\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/60/12224\">",
"         Atrial and ventricular septal defects",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/1/12306\">",
"         Patient information: Patent foramen ovale (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Atrial septal defect (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/atrial-septal-defect-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8615593\">",
"      <span class=\"h1\">",
"       What is atrial septal defect?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Atrial septal defect (also called &ldquo;ASD&rdquo;) is a hole between 2 sections of the heart. The heart is divided into 4 sections, called &ldquo;chambers.&rdquo; People with an ASD have a hole between the 2 upper chambers called the &ldquo;atria&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef83029 \" href=\"UTD.htm?11/60/12224\">",
"       figure 1",
"      </a>",
"      ). Having a large or medium sized hole can change how blood flows through the heart. Plus, it can make the heart work harder than it should. This can cause health problems.",
"     </p>",
"     <p>",
"      A person who has ASD was born with it. He or she might only have ASD, or have other heart problems, too. Some conditions that run in families cause ASD.",
"     </p>",
"     <p>",
"      An ASD causes a heart murmur. This is an extra sound doctors or nurses hear when they listen to the heart with a stethoscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8615608\">",
"      <span class=\"h1\">",
"       What are the symptoms of atrial septal defect?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms are different for each person. They depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The size of the ASD",
"       </li>",
"       <li>",
"        Where the ASD is",
"       </li>",
"       <li>",
"        Whether the person has other heart problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A baby or child who has a small ASD might not have any symptoms. The doctor or nurse might find a heart murmur at a routine checkup.",
"     </p>",
"     <p>",
"      A newborn baby with ASD might have skin that looks blue for a short time right after birth. A doctor or nurse in the delivery room or nursery might notice that the baby looks blue. He or she might also find a heart murmur that could be a sign of ASD.",
"     </p>",
"     <p>",
"      A baby who has a large ASD might get a lot of colds. He or she might not gain weight as quickly as other babies. Often, babies and children with ASD are smaller than other children their age. &nbsp;",
"     </p>",
"     <p>",
"      If a large or medium sized ASD is not found and treated, it can cause symptoms by age 40. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Abnormal heartbeat -- The heart might feel like it is racing or skipping beats.",
"       </li>",
"       <li>",
"        Trouble exercising or doing other physical activities &ndash; A person with an ASD might also get tired easily just from normal daily activities. &nbsp;",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Skin that looks blue",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8615623\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a baby has ASD, a doctor or nurse might find it soon after birth. But this does not always happen. See the doctor or nurse if your baby:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Does not gain weight or grow as quickly as other children",
"       </li>",
"       <li>",
"        Gets a lot of colds or other infections",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you or your child have an abnormal heartbeat, trouble exercising, or trouble breathing, see a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8615638\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If the doctor or nurse thinks your child might have an ASD, he or she can order the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram (ECG or EKG)&nbsp;&mdash; This test measures the electrical activity in the heart. It might show a pattern of abnormal electrical activity that is common in people who have ASD. &nbsp;",
"       </li>",
"       <li>",
"        A chest X-ray &mdash; A chest X-ray might be normal, or show changes to the heart caused by a large ASD.",
"       </li>",
"       <li>",
"        An echocardiogram &ndash; This test uses sound waves to create a picture of the heart as it beats. It can show the size of the hole in your child&rsquo;s heart. It can also show exactly where the hole is and if there are other heart problems. &nbsp;",
"       </li>",
"       <li>",
"        An MRI &ndash; A few people get this imaging test to see if they have ASD. An MRI creates pictures of the inside of the body. Doctors do an MRI to get more information about ASD and other heart conditions. It can show how blood is flowing in the heart.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8615653\">",
"      <span class=\"h1\">",
"       How is atrial septal defect treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a baby or child has a small ASD, doctors might wait to see if the hole closes on its own. If this happens, a child does not need surgery. Small ASDs usually close by the time a child is 2 to 5 years old.",
"     </p>",
"     <p>",
"      Medium or large ASDs are less likely to close on their own. Surgery is usually needed to close the hole. But if an ASD does not cause symptoms, doctors usually wait to do surgery until the child is 2 years old. This is because there is still a small chance the hole will close on its own. &nbsp;",
"     </p>",
"     <p>",
"      If an ASD causes symptoms, doctors do surgery to close the hole and get rid of symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8615668\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=see_link\">",
"       Patient information: Patent foramen ovale (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/31/6642?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83027 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6642=[""].join("\n");
var outline_f6_31_6642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8615593\">",
"      What is atrial septal defect?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8615608\">",
"      What are the symptoms of atrial septal defect?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8615623\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8615638\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8615653\">",
"      How is atrial septal defect treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8615668\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/60/12224\">",
"      Atrial and ventricular septal defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=related_link\">",
"      Patient information: Patent foramen ovale (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6643="Prenatal ultrasound of umbilical arteries along the bladder";
var content_f6_31_6643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal Doppler ultrasound showing umbilical arteries along the bladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral umbilical arteries seen lateral to the bladder in the center on color Doppler.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6643=[""].join("\n");
var outline_f6_31_6643=null;
var title_f6_31_6644="Prednicarbate: Drug information";
var content_f6_31_6644=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednicarbate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/30/3556?source=see_link\">",
"    see \"Prednicarbate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7796?source=see_link\">",
"    see \"Prednicarbate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dermatop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dermatop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Topical: Cream, ointment: Apply a thin film to affected area twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11431718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7796?source=see_link\">",
"      see \"Prednicarbate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Children &ge;10 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.1% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatop&reg;: 0.1% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.1% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatop&reg;: 0.1% (60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11431802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Do not use on diaper area, face, groin area, underarm or open wounds. Do not cover with occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dermatop&reg; may be confused with Dimetapp&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Skin atrophy (children 8%; adults 1%), mild telangiectasia (children 5%), shininess (children 3%), thinness (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acneiform eruptions, allergic contact dermatitis, burning, edema, folliculitis, hypopigmentation, miliaria, paresthesia, perioral dermatitis, pruritus, rash, secondary infection, striae, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednicarbate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur and it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Adverse systemic effects including hyperglycemia, glycosuria, fluid and electrolyte changes, and HPA suppression may occur when used on large surface areas, for prolonged periods, or with an occlusive dressing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diaper dermatitis: Do not use for diaper dermatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Petrolatum-based: Avoid contact with latex-containing products; may damage or reduce effectiveness of latex condoms or diaphragms. If contact occurs, throw away latex product. Do not use prednicarbate intravaginally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; do not use intravaginally. Avoid contact with eyes, face, underarms, or groin area. Do not use occlusive dressings; discontinue use if irritation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11431693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using prednicarbate during pregnancy. However, intrauterine growth retardation has been reported with other topical steroids. Avoid use in large amounts for long periods of time during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11431694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11431695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. The extent of topical absorption is variable. Use with caution while breast-feeding; do not apply to nipples.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Dermatop External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 g): $105.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Prednicarbate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $23.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Dermatop External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 g): $100.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Prednicarbate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $30.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F212802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Batmen (ES);",
"     </li>",
"     <li>",
"      Dermatop (BG, BR, CZ, DE, HR, IT, TR);",
"     </li>",
"     <li>",
"      Dermin Cream (KP);",
"     </li>",
"     <li>",
"      Dermotop (HR);",
"     </li>",
"     <li>",
"      Peitel (ES);",
"     </li>",
"     <li>",
"      Peitel Crema (CR, DO, EC, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Prednitop (AT, CH);",
"     </li>",
"     <li>",
"      Primaderm (AR);",
"     </li>",
"     <li>",
"      Skinpred (CO);",
"     </li>",
"     <li>",
"      Sterotop (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F212785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical corticosteroids have anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative actions",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/31/6644/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9807 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6644=[""].join("\n");
var outline_f6_31_6644=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212804\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212805\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212822\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212806\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431718\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212807\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212795\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212782\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431802\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212796\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212820\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212798\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212786\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299937\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212790\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212791\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431693\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431694\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431695\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212801\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212802\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212785\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/30/3556?source=related_link\">",
"      Prednicarbate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7796?source=related_link\">",
"      Prednicarbate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6645="Schneiderian papilloma Light";
var content_f6_31_6645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schneiderian (cylindric cell) papilloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the characteristic eosinophilic columnar epithelium (black arrow) with microabcesses (black arrowheads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6645=[""].join("\n");
var outline_f6_31_6645=null;
var title_f6_31_6646="Complications of therapeutic plasma exchange";
var content_f6_31_6646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of therapeutic plasma exchange",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Joy L Fridey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6646/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/31/6646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic plasma exchange (TPE, plasmapheresis) is an extracorporeal blood purification technique designed for the removal of pathogenic substances, such as antibodies, immune complexes, or large molecular weight substances from the plasma. This topic review will discuss the complications associated with this procedure. The indications for, prescription, and technique of TPE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12597?source=see_link\">",
"     \"Indications for therapeutic plasma exchange\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of the reported complications from over 15,000 plasma exchange treatments found that adverse reactions were substantially more common with fresh frozen plasma (FFP) than with albumin replacement (20 versus 1.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The most frequent problems are citrate anticoagulant-induced symptoms of hypocalcemia, such as paresthesias (due to binding of ionized (free) calcium to citrate), muscle cramps, nausea and vomiting, hypotension, and, in extreme, tetany; allergic symptoms including urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritus can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/6\">",
"     6",
"    </a>",
"    ]. More serious complications, such as severe anaphylactoid reactions or transfusion-related acute lung injury (TRALI), can follow the administration of FFP and other plasma-containing replacement fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/7\">",
"     7",
"    </a>",
"    ] or can rarely occur in patients receiving treatment with ACE inhibitors receiving albumin as the replacement fluid. The overall incidence of death is 0.03 to 0.05 percent (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;TPE can lead to a reduction in blood pressure that may be due to a decrease in intravascular volume. A certain proportion of whole blood must necessarily be extracorporeal during the procedure, generally around 200 ml. With continuous flow technology, the extracorporeal volume is usually no more than 15 percent of the patient's intravascular volume; however, instrumentation which utilizes discontinuous flow technology may have higher extracorporeal volumes. Infusing additional intravascular fluid or increasing the return rate can return the blood pressure toward the baseline level.",
"   </p>",
"   <p>",
"    If a fall in blood pressure is accompanied by a decrease in pulse rate, diaphoresis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    syncope, it is likely that a",
"    <strong>",
"     vasovagal reaction",
"    </strong>",
"    is occurring. Lowering the patient's head, using ammonium salts, and stopping the procedure temporarily are the appropriate responses to this type of reaction. Modest fluid boluses with normal saline can also improve the patient&rsquo;s symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of shortness of breath or dyspnea suggests the presence of pulmonary edema due to fluid overload. Noncardiogenic edema can rarely occur and, if the blood components being reinfused are not adequately anticoagulated, massive pulmonary emboli can ensue. The latter is a rare occurrence, since state-of-the-art blood cell separators control and monitor anticoagulant volumes.",
"   </p>",
"   <p>",
"    Allergic reactions associated with bronchospasm can be observed in patients receiving FFP as the replacement fluid. In addition, hypotension, dyspnea, and chest pain may be produced by complement-mediated membrane bioincompatibility or sensitivity to the ethylene oxide used as a membrane sterilant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Appropriate pharmacologic intervention should be instituted to manage allergic reactions, and may include antihistamines, epinephrine, or corticosteroids, depending upon the severity of the symptoms. If an anaphylactic-like reaction occurs during plasmapheresis with albumin, albumin from a different lot should be used for subsequent procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784755\">",
"    <span class=\"h2\">",
"     Transfusion-related acute lung injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-related acute lung injury (TRALI) is a form of acute lung injury, usually caused by the infusion of Class I or II HLA or anti-neutrophil antibodies from a donor's plasma, which react with a cognate antigen on the recipient's leukocytes. Resulting leukoagglutination in the pulmonary circulation is heralded by the sudden onset of non-cardiogenic pulmonary edema, acute dyspnea, and other symptoms such as hypotension and cyanosis during or within approximately six hours of infusion. Treatment is supportive, and in severe cases the patient may need ventilatory support. The fatality rate is 10 to 15 percent.",
"   </p>",
"   <p>",
"    This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Citrate-induced hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Citrate is infused either as the anticoagulant for the extracorporeal system or in the FFP administered as a replacement fluid. It binds to ionized calcium to form soluble",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    , thereby lowering the ionized, but not the total, serum calcium concentration. Potential early symptoms of hypocalcemia include perioral and distal extremity paresthesias or numbness. Slowing the rate of exchange may cause resolution of symptoms. Severe reactions can include tetany, prolongation of the QT interval, or arrhythmias.",
"   </p>",
"   <p>",
"    A successful prophylactic regimen consists of infusing (over 15 to 30 minutes) one 10 mL ampul of 10 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    , beginning 15 minutes after the start of plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. The calcium infusion can be repeated if the apheresis therapy will last substantially longer than one hour. In one of the author's experience (AAK), this regimen reduced the incidence of symptomatic hypocalcemia from 9.1 percent to 1 percent of treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/1\">",
"     1",
"    </a>",
"    ]. The other author (JLF) generally uses oral calcium supplements, reserving intravenous therapy for patients who cannot take oral calcium or the occasional patient who develops severe hypocalcemia or symptoms that do not improve with the administration of oral calcium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Citrate-induced metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One other complication of citrate administration is the development of metabolic alkalosis in patients with concurrent renal failure (as in anti-GBM antibody disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/11\">",
"     11",
"    </a>",
"    ]. Metabolism of the excess citrate generates bicarbonate, the excretion of which is limited by the renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coagulation abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange with albumin or other non-FFP replacement fluid produces a predictable decrease in clotting factors that may predispose to bleeding. After a single plasma volume exchange, for example, the prothrombin time increases by 30 percent and the partial thromboplastin time doubles; these changes tend to return towards normal within four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. However, more severe and long-lasting changes can be induced when multiple exchanges are performed over a short period, eg, three or more treatments per week [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, one or more liters (three to four units per liter) of FFP may be substituted as the replacement fluid in patients at risk for bleeding, as with hemoptysis in anti-GBM antibody disease or immediately following a renal biopsy; the plasma should be administered at the end of procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of immunoglobulins and complement can in theory lead to an immunodeficient state, leaving the patient prone to infection. Previous reports of patients treated with plasma exchange for glomerulonephritis have suggested an increased incidence of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/14\">",
"     14",
"    </a>",
"    ]. These patients, however, were also treated with immunosuppressive agents and were often noted to be granulocytopenic, a complication unlikely to be induced by apheresis. In a randomized, controlled trial of plasmapheresis in patients with lupus nephritis, patients receiving apheresis were not more prone to infection than other patients receiving a similar immunosuppressive regimen but not plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Monitoring IgG levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated apheresis treatments with albumin replacement will predictably deplete the patient's reserve of immunoglobulins, resulting in low serum IgG levels and an increased risk of infection. The need for monitoring serum IgG levels depends upon a number of factors, including how frequently the exchanges are performed, how many blood volumes are exchanged with each procedure, the immune status of the patient, and the patient's ability to produce immunoglobulins.",
"   </p>",
"   <p>",
"    For a patient undergoing aggressive therapeutic plasmapheresis (eg, 2 to 3 plasma volumes replaced per procedure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consecutive daily procedures), without plasma exchange, IgG levels will be predictably low, and a baseline IgG should be ordered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Although IgG replacement has not been tested in this setting, we give a single infusion of intravenous immune globulin (IVIG, 100 to 400",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    if IgG levels subsequently fall below 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and a systemic infection occurs during this period. This will restore the plasma immunoglobulin concentration toward normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Viral transmission by FFP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent estimates of the per unit risk of transfusion-acquired viral disease in the United States are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"     table 1",
"    </a>",
"    ). A single plasma volume exchange with FFP (approximately three liters) represents 10 to 15 units of FFP from an approximately equal number of donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize exposure to infectious diseases when plasma is used for replacement, patients should be given large-volume plasma units collected from a single donor rather than multiple single units of FFP (which would expose the patient to multiple allogeneic blood products). Large volume units contain 400 to 600 mL of plasma versus 200 mL for single FFP units. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    may be beneficial in patients in whom a large amount of FFP is expected to be given (as in TTP or patients at high risk for bleeding).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anaphylactic reactions to FFP",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, anaphylactic reactions to FFP or other plasma containing replacement fluid are the most common cause of serious complications and death associated with plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These reactions have been reported in up to 21 percent of patients, and are most often characterized by fever, rigors, urticaria, wheezing, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Cardiopulmonary collapse is rare. The risk and severity of anaphylactoid reactions can be diminished by pretreatment with ephedrine, corticosteroids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/20\">",
"     20",
"    </a>",
"    ]. If anaphylaxis occurs due to the presence of anti-IgA in a truly IgA deficient patient, it will be necessary to obtain plasma from IgA deficient donors. Usually this product is only available from a rare donor registry, and it be may become difficult to obtain enough units to perform multiple TPEs on a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Albumin replacement can, by dilution, induce a 25 percent reduction in the plasma potassium concentration in the postpheresis period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/21\">",
"     21",
"    </a>",
"    ]. This complication and the risk of hypokalemia-induced arrhythmias can be minimized by ensuring that each liter of albumin contains 4 meq of potassium per liter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drug removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial drug removal by plasma exchange should be anticipated for those drugs which are highly protein bound and therefore primarily limited to the vascular space. Among drugs used to treat renal diseases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    are not substantially removed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/22\">",
"     22",
"    </a>",
"    ], while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are removed to some extent. This potential problem can be circumvented by administering the drug after a plasma exchange treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Problems with vascular catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual problems of indwelling vascular catheters can be encountered when such devices are used for venous access. These include infection, pain and nerve damage, thrombosis, perforation, dissecting hematomas, or arteriovenous fistulas. Many of these complications can also occur if peripheral veins are used for TPE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flushing, hypotension, abdominal cramping, and other gastrointestinal symptoms have been reported during plasmapheresis in patients receiving angiotensin converting enzyme inhibitors. These symptoms were observed when albumin was the replacement fluid, and the patient had taken the medication within 24 to 30 hours of plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one report of 299 consecutive patients undergoing TPE, these atypical symptoms occurred in all 14 patients receiving an ACE inhibitor versus only 7 percent of those not treated with this medication [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Why these symptoms occur is not clear. One possibility is increased kinin generation which has been thought to account for the angioedema that can occur with ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .) Regardless of the mechanism, it has been recommended that ACE inhibitors be withheld for 24 hours prior to apheresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported case fatality rate for TPE is 3 to 5 per 10,000 (0.03 to 0.05 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. In more than 50 TPE-associated deaths since 1989, respiratory or cardiac mishaps were most common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6646/abstract/25\">",
"     25",
"    </a>",
"    ]. Cardiac arrhythmias were frequently observed, especially in those receiving FFP; the suspected etiology was a reduced ionized calcium concentration but a cause-and-effect relationship has not been proven.",
"   </p>",
"   <p>",
"    Among patients suffering respiratory deaths, acute respiratory distress and symptoms of noncardiogenic pulmonary edema were observed shortly before death; these patients were also being infused with FFP. Anaphylaxis, vascular complications, hepatitis, sepsis, and thrombosis were other, less common causes of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16026803\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic plasma exchange (TPE, plasmapheresis) is an extracorporeal blood purification technique designed for the removal of pathogenic substances, such as antibodies, antigen-antibody complexes, and large molecular weight substances from the plasma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse reactions from TPE are substantially more common with fresh frozen plasma (FFP) than with albumin replacement (20 versus 1.4 percent). The most frequent problems are citrate-induced paresthesias, muscle cramps, and urticaria. More serious complications, such as severe anaphylactoid reactions, typically follow the administration of FFP and other plasma-containing replacement fluid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall incidence of death following TPE is 0.03 to 0.05 percent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/1\">",
"      Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/2\">",
"      Norda R, Stegmayr BG, Swedish Apheresis Group. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003; 29:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/3\">",
"      Basic-Jukic N, Kes P, Glavas-Boras S, et al. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005; 9:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/4\">",
"      Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher 2007; 22:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/5\">",
"      Yeo FE, Bohen EM, Yuan CM, et al. Therapeutic plasma exchange as a nephrological procedure: a single-center experience. J Clin Apher 2005; 20:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/6\">",
"      Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/7\">",
"      Huestis DW. Mortality in therapeutic haemapheresis. Lancet 1983; 1:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/8\">",
"      J&oslash;rstad S. Biocompatibility of different hemodialysis and plasmapheresis membranes. Blood Purif 1987; 5:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/9\">",
"      Nicholls AJ, Platts MM. Anaphylactoid reactions due to haemodialysis, haemofiltration, or membrane plasma separation. Br Med J (Clin Res Ed) 1982; 285:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/10\">",
"      Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990; 38:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/11\">",
"      Pearl RG, Rosenthal MH. Metabolic alkalosis due to plasmapheresis. Am J Med 1985; 79:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/12\">",
"      Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol 1981; 48:627.",
"     </a>",
"    </li>",
"    <li>",
"     Gelabert A, Puig L, Maragall S, et al. Coagulation alterations during massive plasmapheresis. In: Plasma Exchange, Sieberth HG (Ed), Schattauer Verlag, Stuttgart 1980. p.71.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/14\">",
"      Wing EJ, Bruns FJ, Fraley DS, et al. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980; 244:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/15\">",
"      Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991; 114:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/16\">",
"      Kaplan AA. Towards a rational prescription of plasma exchange: The kinetics of immunoglobulin removal. Semin Dial 1992; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/17\">",
"      Keller AJ, Urbaniak SJ. Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol 1978; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/18\">",
"      Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/19\">",
"      Bambauer R, Jutzler GA, Albrecht D, et al. Indications of plasmapheresis and selection of different substitution solutions. Biomater Artif Cells Artif Organs 1989; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/20\">",
"      Apter AJ, Kaplan AA. An approach to immunologic reactions associated with plasma exchange. J Allergy Clin Immunol 1992; 90:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/21\">",
"      Orlin JB, Berkman EM. Partial plasma exchange using albumin replacement: removal and recovery of normal plasma constituents. Blood 1980; 56:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/22\">",
"      Stigelman WH Jr, Henry DH, Talbert RL, Townsend RJ. Removal of prednisone and prednisolone by plasma exchange. Clin Pharm 1984; 3:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/23\">",
"      Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994; 34:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6646/abstract/24\">",
"      Brecher ME, Owen HG, Collins ML. Apheresis and ACE inhibitors. Transfusion 1993; 33:963.",
"     </a>",
"    </li>",
"    <li>",
"     Technical Manual, 17th ed, Roback JD (Ed), American Association of Blood Banks, Bethesda 2011.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7942 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6646=[""].join("\n");
var outline_f6_31_6646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16026803\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784755\">",
"      Transfusion-related acute lung injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Citrate-induced hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Citrate-induced metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Monitoring IgG levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Viral transmission by FFP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anaphylactic reactions to FFP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drug removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Problems with vascular catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Angiotensin converting enzyme inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16026803\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/59/31676\" title=\"table 1\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6647="Herpes simplex virus infection of the esophagus";
var content_f6_31_6647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Herpes simplex virus infection of the esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Dori F Zaleznik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6647/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/31/6647/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagitis is most often caused by noninfectious conditions, such as gastroesophageal reflux disease, whereas esophageal infection occurs predominantly in hosts with impaired immunity resulting from chemotherapy, transplantation, or HIV infection. The most common causes of infectious esophagitis include candida, cytomegalovirus (CMV), and herpes simplex virus (HSV).",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, clinical manifestations, diagnosis, and treatment of HSV esophagitis. Topics on candidal and CMV esophagitis are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) infection of the esophagus is usually observed in patients who are immunocompromised, but can occasionally be seen in patients who are immunocompetent. The vast majority of infections are related to HSV type 1, although HSV-2 has occasionally been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV esophagitis may result from reactivation of HSV with spread of virus to the esophageal mucosa by way of the vagus nerve or by direct extension of oral&ndash;pharyngeal infection into the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV esophagitis occurs most frequently in solid organ and bone marrow transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. HSV and cytomegalovirus (CMV) were the most commonly identified pathogens (48 percent each) in a study of 21 patients with endoscopically proven esophagitis who had undergone bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/8\">",
"     8",
"    </a>",
"    ]. HSV esophagitis has also been reported in the setting of acute rejection and intensive immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV is a less common cause of esophagitis in patients with HIV infection than in transplant recipients. In three illustrative reports, esophagitis from HSV-1 infection was identified in only 3 to 5 percent of HIV-infected patients with esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In most reports, the most common cause of esophagitis in patients with advanced AIDS was candida, whereas the most common viral cause was CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/10\">",
"     10",
"    </a>",
"    ]. Both infections coexist in some patients. However, the incidence of infectious esophagitis from any cause has declined since the introduction of potent antiretroviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link&amp;anchor=H25#H25\">",
"     \"Factors affecting HIV progression\", section on 'Impact of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunocompetent patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagitis due to HSV-1 has been described in otherwise healthy patients in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/1,11-17\">",
"     1,11-17",
"    </a>",
"    ]. In one review of 56 patients (39 men and 17 women), the mean age at presentation was 35 years with cases among men predominating in those under 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/1\">",
"     1",
"    </a>",
"    ]. Cases of HSV-1 esophagitis have also been reported in immunocompetent children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients usually present with odynophagia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. In the review of 56 immunocompetent patients, fever and retrosternal chest pain occurred in 52 and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/1\">",
"     1",
"    </a>",
"    ]. These latter symptoms are also a feature of herpes simplex virus (HSV) esophagitis in immunocompromised individuals. Patients can have coexistent herpes labialis or oropharyngeal ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/19\">",
"     19",
"    </a>",
"    ]. Complications that have been described in older case reports include bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/20\">",
"     20",
"    </a>",
"    ], the development of a tracheoesophageal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and food impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/23\">",
"     23",
"    </a>",
"    ]. A case of intractable hiccups in association with HSV esophagitis has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of herpes simplex virus (HSV) esophagitis is usually based on endoscopic findings confirmed by histopathological examination of the observed lesions. Suggestive findings may sometimes be seen during a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60135 \" href=\"UTD.htm?28/39/29310\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lesions usually affect the squamous mucosa of the distal esophagus where the earliest manifestation is a vesicle, although this early stage is rarely seen on endoscopy. The lesions coalesce to form ulcers (usually less than 2 cm), frequently with normal-appearing intervening mucosa (",
"    <a class=\"graphic graphic_picture graphicRef83681 \" href=\"UTD.htm?10/53/11090\">",
"     picture 1",
"    </a>",
"    ). The ulcers are well circumscribed and have a \"volcano-like\" appearance, distinguishing them from the ulcers seen in cytomegalovirus (CMV) infection, which tend to be linear or longitudinal and deeper [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. Exudates, plaques, or diffuse erosive esophagitis may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies or brushing should be taken from the edge of an ulcer where viral cytopathic effects are most likely to be present. Histologic findings include multinucleated giant cells, with ground-glass nuclei and eosinophilic inclusions (Cowdry type A inclusion bodies) that occupy up to one-half of the nuclear volume (",
"    <a class=\"graphic graphic_picture graphicRef67790 \" href=\"UTD.htm?10/41/10902\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/27\">",
"     27",
"    </a>",
"    ]. Immunohistochemical stains for HSV glycoproteins may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/28\">",
"     28",
"    </a>",
"    ]. Viral culture of suspicious lesions should be performed during endoscopy to confirm the diagnosis and to identify resistant viral isolates in patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Qualitative and quantitative polymerase chain reaction (PCR) testing has been investigated to detect HSV DNA from biopsy samples [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Efforts are also being made to assess whether determining a tissue viral load could improve specificity and positive predictive values from PCR testing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes other infectious causes of esophagitis (mainly cytomegalovirus [CMV] and candida). Although candida is the most common fungal cause of esophagitis, other fungal infections, including cryptococcosis, histoplasmosis, blastomycosis, and aspergillosis have rarely been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/30\">",
"     30",
"    </a>",
"    ]. Other pathogens, such as mycobacteria and nocardia, have occasionally been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In patients with advanced HIV infection, idiopathic aphthous ulcers have been described in up to one-fourth of patients with esophageal symptoms who did not respond to empiric antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diagnostic considerations include noninfectious causes of esophagitis, particularly pill esophagitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=see_link\">",
"     \"Medication-induced esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of herpes simplex virus (HSV) esophagitis depends upon the host's underlying immune status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised hosts should be treated with a longer duration of therapy than is typically given for less invasive HSV infection (ie, genital HSV). For immunosuppressed patients able to take oral medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg PO five times a day for 14 to 21 days) is effective and has few side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     Famciclovir",
"    </a>",
"    (500 mg three times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1 gram three times daily) can also be considered in patients able to tolerate oral therapy, although there is limited experience with these drugs in HSV esophagitis. Famciclovir and valacyclovir are considered comparable in potency in the treatment of other HSV infections and have the advantage of decreased pill burden; however, they are generally more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6308?source=see_link\">",
"     \"Famciclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous resolution usually occurs in immunocompetent hosts after one to two weeks, although patients may respond more quickly if treated with a short course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . While there are no trials of acyclovir in immunocompetent patients with HSV-1 esophagitis, case reports and treatment experience with acyclovir in immunocompetent patients with oral and genital herpes suggests therapeutic benefit in hastening resolution of lesions. Symptoms have been reported to respond promptly and acyclovir has proven safe in immunocompetent patients treated with other herpes infections. In patients who are NOT immunocompromised, we suggest treatment with a short course of oral acyclovir (200 mg PO five times a day or 400 mg PO three times a day for 7 to 10 days) unless symptoms already appear to be abating.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of patients with severe odynophagia or dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe odynophagia may require hospitalization for parenteral antiviral therapy, pain management, and hydration or alimentation.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every eight hours for 7 to 14 days) can be used for those who are unable to swallow. Patients who rapidly improve can be switched to oral therapy to complete their therapeutic course.",
"    <br/>",
"    <br/>",
"    As of November 2012, there is a shortage of IV acyclovir in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"     US Food and Drug Administration&rsquo;s web site",
"    </a>",
"    for information about the availability of IV acyclovir. If IV acyclovir is not available, an alternative IV regimen can be used. Specific recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H13970285#H13970285\">",
"     \"Acyclovir: An overview\", section on 'Esophageal herpes simplex infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Swallowed viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    oral topical solution (15 mL of a 2 percent formulation) with or without an antacid can be tried to relieve pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/34\">",
"     34",
"    </a>",
"    ], but in our experience is usually only of modest benefit. About 35 percent of the dose is absorbed; thus ingestion should be limited to no more than 300 mg lidocaine (viscous) per dose for patients weighing greater than 65 kg and 4.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    lidocaine (viscous) per dose for patients weighing 65 kg or less, and no more than eight doses per day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drug-resistant HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not respond to therapy may have virus resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    resulting from mutations within the thymidine kinase (TK) or, less commonly, the DNA polymerase gene of HSV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/36\">",
"     36",
"    </a>",
"    ]. Viruses with TK mutations are generally cross-resistant to other drugs in this class, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , but remain susceptible to antiviral agents that act directly on DNA polymerase (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    resistance is related to HSV oral mucositis or genital infection. Acyclovir resistance is most commonly seen in immunocompromised patients, those who have undergone chemotherapy, transplantation, or who have HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Many of these patients will have received multiple courses of acyclovir in the past. Resistant HSV can also arise spontaneously from natural variations within the viral population; this is evident from studies that have demonstrated acyclovir resistance in treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/39\">",
"     39",
"    </a>",
"    ]. However, in extensive surveys conducted in the United States and the United Kingdom of immunocompetent hosts, isolation of drug-resistant HSV remains low (approximately 0.1 to 0.7 percent of isolates). Low levels of drug resistance have been attributed to rapid clearing of HSV infection by an intact immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of severe persistent infection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant HSV occur almost exclusively in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/41\">",
"     41",
"    </a>",
"    ]; in immunocompetent hosts, rare cases of drug-resistant virus have cleared without adverse clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    can be effective for immunosuppressed patients with HSV strains known to be resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or for those who do not respond to acyclovir, although foscarnet must be given parenterally and is associated with considerable toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6647/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes simplex virus (HSV) infection of the esophagus is usually observed in patients who are immunocompromised and occurs most frequently in those receiving immunosuppressive agents, such as solid organ and bone marrow transplant recipients. However, it has also been described in otherwise healthy patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunocompetent patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients usually present with odynophagia and dysphagia. Fever, epigastric pain, nausea, vomiting, and heartburn are less frequent. Occasional patients have coexistent herpes labialis or oropharyngeal ulcers.",
"     </li>",
"     <li>",
"      Diagnosis is usually established with an upper endoscopy. Biopsies or brushing should be taken from the edge of an ulcer where viral cytopathic effects are most likely to be present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes other forms of infectious esophagitis, and pill esophagitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are NOT immunocompromised, we suggest treatment with a short course of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (200 mg PO five times a day or 400 mg PO three times a day for 7 to 10 days) unless symptoms already appear to be abating (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunocompetent patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are immunocompromised, we recommend antiviral therapy for 14 to 21 days (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      (400 mg PO five times a day) has potent anti-HSV activity and is generally the least expensive agent.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      afford less frequent dosing if patient adherence is a concern. Intravenous acyclovir (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every eight hours for 7 to 14 days) can be used for those who are unable to swallow. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As of November 2012, there is a shortage of IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      in the United States. If IV acyclovir is not available, an alternative regimen can be used. Specific recommendations are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"       \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-resistant virus should be suspected in patients who do not respond to antiviral therapy within approximately five to seven days. Viruses with thymidine kinase mutations are generally cross-resistant to other drugs in this class, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , but remain susceptible to antiviral agents that act directly on DNA polymerase (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug-resistant HSV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/1\">",
"      Canalejo Castrillero E, Garc&iacute;a Dur&aacute;n F, Cabello N, Garc&iacute;a Mart&iacute;nez J. Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature. Medicine (Baltimore) 2010; 89:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/2\">",
"      Corey L, Spear PG. Infections with herpes simplex viruses (2). N Engl J Med 1986; 314:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/3\">",
"      McBane RD, Gross JB Jr. Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 1991; 37:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/4\">",
"      Mosimann F, Cu&eacute;noud PF, Steinh&auml;uslin F, Wauters JP. Herpes simplex esophagitis after renal transplantation. Transpl Int 1994; 7:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/5\">",
"      McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985; 88:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/6\">",
"      Kang YN, Oh HK, Chang YC, et al. Systemic herpes simplex virus infection following cadaveric renal transplantation: a case report. Transplant Proc 2006; 38:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/7\">",
"      Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/8\">",
"      Wilcox CM, Schwartz DA, Clark WS. Esophageal ulceration in human immunodeficiency virus infection. Causes, response to therapy, and long-term outcome. Ann Intern Med 1995; 123:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/9\">",
"      Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/10\">",
"      Bini EJ, Micale PL, Weinshel EH. Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy. Dig Dis Sci 2000; 45:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/11\">",
"      Ramanathan J, Rammouni M, Baran J Jr, Khatib R. Herpes simplex virus esophagitis in the immunocompetent host: an overview. Am J Gastroenterol 2000; 95:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/12\">",
"      Rodrigues F, Brand&atilde;o N, Duque V, et al. Herpes simplex virus esophagitis in immunocompetent children. J Pediatr Gastroenterol Nutr 2004; 39:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/13\">",
"      Boersma CC, Borowitz SM. Odynophagia. Clin Pediatr (Phila) 2007; 46:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/14\">",
"      Nagri S, Hwang R, Anand S, Kurz J. Herpes simplex esophagitis presenting as acute necrotizing esophagitis (\"black esophagus\") in an immunocompetent patient. Endoscopy 2007; 39 Suppl 1:E169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/15\">",
"      Lee B, Caddy G. A rare cause of dysphagia: herpes simplex esophagitis. World J Gastroenterol 2007; 13:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/16\">",
"      Geraci G, Pisello F, Modica G, et al. Herpes simplex esophagitis in immunocompetent host: a case report. Diagn Ther Endosc 2009; 2009:717183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/17\">",
"      Bando T, Matsushita M, Kitano M, Okazaki K. Herpes simplex esophagitis in the elderly. Dig Endosc 2009; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/18\">",
"      G&eacute;n&eacute;reau T, Lortholary O, Bouchaud O, et al. Herpes simplex esophagitis in patients with AIDS: report of 34 cases. The Cooperative Study Group on Herpetic Esophagitis in HIV Infection. Clin Infect Dis 1996; 22:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/19\">",
"      Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994; 106:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/20\">",
"      Rattner HM, Cooper DJ, Zaman MB. Severe bleeding from herpes esophagitis. Am J Gastroenterol 1985; 80:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/21\">",
"      Obrecht WF Jr, Richter JE, Olympio GA, Gelfand DW. Tracheoesophageal fistula: a serious complication of infectious esophagitis. Gastroenterology 1984; 87:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/22\">",
"      Cirillo NW, Lyon DT, Schuller AM. Tracheoesophageal fistula complicating herpes esophagitis in AIDS. Am J Gastroenterol 1993; 88:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/23\">",
"      Marshall JB, Smart JR 3rd, Elmer C, et al. Herpes esophagitis causing an unsuspected esophageal food bolus impaction in an institutionalized patient. J Clin Gastroenterol 1992; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/24\">",
"      Mulhall BP, Nelson B, Rogers L, Wong RK. Herpetic esophagitis and intractable hiccups (singultus) in an immunocompetent patient. Gastrointest Endosc 2003; 57:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/25\">",
"      Levine MS. Radiology of esophagitis: a pattern approach. Radiology 1991; 179:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/26\">",
"      Wong RC, Abdul-Karim FW. Atypical herpes simplex esophagitis. Gastrointest Endosc 2005; 61:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/27\">",
"      Wilcox CM, Rodgers W, Lazenby A. Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS. Clin Gastroenterol Hepatol 2004; 2:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/28\">",
"      Jazeron JF, Barbe C, Frobert E, et al. Virological diagnosis of herpes simplex virus 1 esophagitis by quantitative real-time PCR assay. J Clin Microbiol 2012; 50:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/29\">",
"      Dekeyser S, El Nady M, Diaz E, et al. [Diagnosis of herpetic esophagitis in the immunocompetent subject by PCR (Herp&egrave;s Consensus G&eacute;n&eacute;rique-Arg&egrave;ne). Report of six cases]. Pathol Biol (Paris) 2009; 57:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/30\">",
"      Sutton FM, Graham DY, Goodgame RW. Infectious esophagitis. Gastrointest Endosc Clin N Am 1994; 4:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/31\">",
"      El-Serag HB, Johnston DE. Mycobacterium avium complex esophagitis. Am J Gastroenterol 1997; 92:1561.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/34\">",
"      Shortsleeve MJ, Levine MS. Herpes esophagitis in otherwise healthy patients: clinical and radiographic findings. Radiology 1992; 182:859.",
"     </a>",
"    </li>",
"    <li>",
"     USP-FDA package insert (adult dosing section). file://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=4124&amp;type=display (Accessed on August 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/36\">",
"      Frobert E, Ooka T, Cortay JC, et al. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005; 49:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/37\">",
"      Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998; 37:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/38\">",
"      Malvy D, Treilhaud M, Bou&eacute;e S, et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 2005; 41:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/39\">",
"      Kriesel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/40\">",
"      Str&aacute;nsk&aacute; R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/41\">",
"      Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/42\">",
"      Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6647/abstract/43\">",
"      Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320:297.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8306 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6647=[""].join("\n");
var outline_f6_31_6647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of patients with severe odynophagia or dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drug-resistant HSV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8306|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/39/29310\" title=\"diagnostic image 1\">",
"      Herpes esophagitis Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8306|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/53/11090\" title=\"picture 1\">",
"      Endoscopy showing ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/41/10902\" title=\"picture 2\">",
"      Herpes esophagitis Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=related_link\">",
"      AIDS-related cytomegalovirus gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6308?source=related_link\">",
"      Famciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6648="Supraorbital and supratrochlear nerve block";
var content_f6_31_6648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supraorbital and supratrochlear nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 589px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This block anesthetizes the forehead and anterior 1/3 of the scalp. To perform, locate the supraorbital nerve foramen in the medial aspect of the supraorbital ridge as shown in A. After cleansing, insert a small needle (25 or 27 gauge) to a depth of 0.5-1 cm just medial and directed towards the foramen as shown in B. Inject one to three mL of local anesthetic. In older children, adolescents, and adults assess for paresthesias as a sign that the needle tip is in contact with the supraorbital or supratrochlear nerve. Allow 5-10 minutes for complete anesthesia to occur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cimpello LB, Deutsch RJ, Dixon C, et al. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6648=[""].join("\n");
var outline_f6_31_6648=null;
var title_f6_31_6649="Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet";
var content_f6_31_6649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6649/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6649/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6649/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6649/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6649/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/31/6649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the natural history of chronic mitral regurgitation (MR) is an essential part of any medical or surgical management plan. The natural history is variable, depending upon the etiology and the stage at which the disease is first diagnosed.",
"   </p>",
"   <p>",
"    The major causes of MR are primary diseases of the valve leaflets (eg, mitral valve prolapse [MVP] and in the past rheumatic heart disease) and secondary (functional) MR due to cardiomyopathy or coronary disease. Among the causes of MR, MVP, infective endocarditis, trauma, and partial rupture of a papillary muscle in the setting of an acute myocardial infarction can lead to a flail (or partial flail) mitral leaflet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best natural history data that are presently available have come from studies of patients with MVP and flail mitral leaflet, which can be caused by MVP. These findings may not apply to MR of other causes, especially ischemic and functional MR.",
"   </p>",
"   <p>",
"    This topic will review the natural history of MVP and of flail mitral leaflet. The indications for surgery in chronic MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF MITRAL VALVE PROLAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of MVP using modern echocardiographic techniques is 0.6 to 2.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The natural history of MVP is generally benign, but serious complications do occur; the most common are infective endocarditis, cerebrovascular accidents, the need for mitral valve surgery, and death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 1970s, clinicians relied on the physical examination and phonocardiogram for the diagnosis of MVP. Reports from that era indicate that serious complications occurred at the rate of approximately 1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In the 1980s, with increasing use of echocardiography, clinical investigators described higher complication rates of approximately 2 to 4 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. These patients, seen at tertiary referral centers, presumably had more serious disease.",
"   </p>",
"   <p>",
"    Although leaflet thickness &gt;5 mm by M-mode echocardiography was associated with increased risk for complications in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/5,8\">",
"     5,8",
"    </a>",
"    ], a larger later series using 2D echocardiography found that leaflet thickness was not an independent predictor of mortality and valvular morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/9\">",
"     9",
"    </a>",
"    ]. In this community study of 833 patients diagnosed with asymptomatic MVP and followed longitudinally in the Olmsted County, cardiac mortality was best predicted by presence of MR and left ventricular dysfunction at the time of diagnosis, while risk factors for cardiac morbidity (defined as occurrence of heart failure, thromboembolic events, endocarditis, atrial fibrillation, and need for cardiac surgery) included age &ge;50 years, left atrial enlargement, MR, flail leaflet, and atrial fibrillation present at baseline echocardiography.",
"   </p>",
"   <p>",
"    Our current understanding is that patients with MVP constitute a heterogeneous group in which risk factors for a widely varying prognosis can be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This was best illustrated in a community-based retrospective review of the course of 833 residents of Olmsted County, Minnesota who were first diagnosed with",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    MVP between 1989 and 1998; the patients had little comorbidity or cardiovascular history [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of MVP was suspected from auscultatory findings in 67 percent and was confirmed in all patients by echocardiography, which was performed for other reasons in 33 percent.",
"   </p>",
"   <p>",
"    At a median follow-up of 5.4 years, the estimated 10 year overall and cardiovascular mortality were 19 and 9 percent, respectively. Cardiovascular morbidity occurred in 30 percent and MVP-related events (death or heart failure related to MVP, endocarditis, or mitral valve surgery) occurred in 20 percent. Valve surgery was performed in 65 patients (7.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factor for cardiovascular mortality in the Olmsted County study was moderate to severe MR by echocardiography, which was present in 131 patients (16 percent) (",
"    <a class=\"graphic graphic_movie graphicRef65137 \" href=\"UTD.htm?31/23/32115\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78402 \" href=\"UTD.htm?20/12/20672\">",
"     movie 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar findings were noted in another report in which the likelihood of developing MVP-related complications was directly related to the severity of the MR (",
"    <a class=\"graphic graphic_figure graphicRef57338 \" href=\"UTD.htm?33/17/34077\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A less common primary risk factor for cardiovascular mortality in the Olmsted County study, present in 3.7 percent of patients, was a left ventricular ejection fraction (LVEF) less than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10\">",
"     10",
"    </a>",
"    ]. Secondary risk factors that were independently predictive of cardiovascular morbidity were slight MR, left atrial dimension &ge;40 mm, flail leaflet, atrial fibrillation (AF), and age &ge;50 years.",
"   </p>",
"   <p>",
"    These findings, which were similar whether the diagnosis was made by auscultation or incidental echocardiography, were then used to identify patients in different prognostic groups for both cardiovascular mortality and morbidity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 430 patients (52 percent of the population) with 0 to 1 secondary risk factors and no risk factor for mortality had a generally good prognosis. The 10-year mortality was 5 percent, which was not significantly different from expected, and the rates of cardiovascular and MVP-related morbidity were 0.5 and 0.2 percent per year.",
"     </li>",
"     <li>",
"      The 250 patients (30 percent) with &ge;2 secondary risk factors and no risk factor for mortality had a 10 year cardiovascular mortality similar to expected but higher rates of cardiovascular and MVP-related morbidity (6.2 and 1.7 percent per year).",
"     </li>",
"     <li>",
"      The 153 patients (18 percent) with a risk factor for mortality (moderate to severe MR or LVEF &lt;50 percent) had marked increases in the rate of overall and cardiovascular mortality (4.5 and 3.4 percent per year) and cardiovascular and MVP-related morbidity (18.5 and 15 percent per year).",
"     </li>",
"     <li>",
"      The five-year rate of cardiovascular mortality or morbidity in the low, moderate, and high-risk groups were 1, 22, and 49 percent, respectively, in patients under age 50; the values were 3, 26, and 66 percent in older patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential prognostic value of serum concentrations of brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with MR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H14009091#H14009091\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Natriuretic peptide levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Sex differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more women than men have MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/2,10\">",
"     2,10",
"    </a>",
"    ], complications have been reported more frequently in men [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Sex differences in MVP presentation and outcomes were evaluated in a Mayo Clinic study of 4461 women and 3758 men diagnosed with MVP by echocardiography from 1989 to 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to men, women had less posterior prolapse (22 versus 31 percent), less flail (2 versus 8 percent), more valve thickening (32 versus 28 percent) and less frequent severe regurgitation (19 versus 23 percent).",
"     </li>",
"     <li>",
"      Among patients with severe regurgitation, women were less likely than men to undergo mitral valve surgery (52 versus 60 percent).",
"     </li>",
"     <li>",
"      At 15 years, women with no or mild MR had better odds of survival than men (87 versus 77 percent) but those with severe regurgitation had worse survival than men (60 versus 68 percent). Survival 10 years after surgery was similar in women and men (77 versus 79 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings led the investigators to postulate that use of the absolute (rather than body size adjusted) cavity size thresholds might cause delay in referral of women for mitral surgery. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Development of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the Olmsted County study, AF is one of the secondary risk factors for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10\">",
"     10",
"    </a>",
"    ]. Another report from Olmsted County assessed the rate of development of AF in 89 patients with MVP (and grade 3 or 4 MR) and 360 with flail leaflets; all of the patients were in sinus rhythm at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/17\">",
"     17",
"    </a>",
"    ]. The rate of development of AF was about 5 percent per year with both types of lesions; the major independent risk factors were age &ge;65 years and baseline left atrial dimension &ge;50 mm. The onset of AF was associated with increases in cardiac mortality and morbidity with medical management.",
"   </p>",
"   <p>",
"    Another report evaluated the prevalence of AF in patients with MVP who were about to undergo mitral valve repair or valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/18\">",
"     18",
"    </a>",
"    ]. Among 246 such patients, 37 (15 percent) were in AF and another 32 (13 percent) had a history of AF that reverted to sinus rhythm either spontaneously or with antiarrhythmic drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its relatively high prevalence (0.6 to 2.4 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]), MVP is the most common valvular cause of chronic MR. In the community-based Olmsted County study cited above, moderate to severe MR was present in 16 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10\">",
"     10",
"    </a>",
"    ]. A similar rate of moderate to severe MR on echocardiography (23 percent) was noted in a much smaller series from the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The valvular lesion in MVP is characterized by thickening and degeneration of the leaflets and chordae (",
"    <a class=\"graphic graphic_movie graphicRef57557 \" href=\"UTD.htm?23/5/23646\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76601 \" href=\"UTD.htm?8/32/8707\">",
"     movie 4",
"    </a>",
"    ). These changes reflect repeated damage to the valve leaflets, which deforms the valve, thereby preventing proper coaptation of the leaflets. The mitral annulus dilates and increasingly leaks as regurgitation worsens. An increase in prolapse may further stretch and damage the chordae tendineae. Weakened chordae can rupture suddenly, producing a flail mitral leaflet and severe mitral regurgitation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Natural history of flail mitral leaflet'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hemodynamic progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation in moderate to severe MVP tends to progress, leading to a worsening of hemodynamic status and ultimately to clinical symptoms. Progression is usually gradual but can be abrupt if chordal rupture occurs. The severity of MR is an essential determinant of the hemodynamic alterations, left ventricular remodeling, and outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course of MR in MVP was evaluated in a prospective study of 74 patients with organic MR (64 with MVP, 10 of whom developed a new flail leaflet) who underwent two Doppler echocardiographic examinations that were separated by an average of 1.5 years. The following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regression of the regurgitant volume by more than 8 mL occurred in 11 percent",
"     </li>",
"     <li>",
"      Progression of the regurgitant volume by more than 8 mL occurred in 51 percent",
"     </li>",
"     <li>",
"      The mean rate of increase in regurgitant volume was 5.9 mL per year in patients with stable MVP and 18.4 mL per year in the patients with MVP who developed a new flail leaflet",
"     </li>",
"     <li>",
"      The effective regurgitant orifice increased by a mean of 6.2 mm",
"      <sup>",
"       2",
"      </sup>",
"      per year in patients with stable MVP and 10.6 mm",
"      <sup>",
"       2",
"      </sup>",
"      per year in the patients with MVP who developed a new flail leaflet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In multivariate analysis, there were two independent predictors of increased regurgitant volume:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression of the valvular lesion, particularly a new flail leaflet, which occurred in 10 of the 64 patients (16 percent) with MVP and",
"     </li>",
"     <li>",
"      Progressive increase in mitral annulus diameter, which was usually due to left ventricular and left atrial enlargement and which reduces leaflet coaptation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the major predictor of a reduction in regurgitant volume was a fall in blood pressure. However, no significant effect from treatment was seen, a finding consistent with the uncertain benefit of oral vasodilator therapy in patients with chronic MR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=see_link\">",
"     \"Vasodilator therapy in chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that as many as 10 percent of patients with MVP will require mitral valve surgery in their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/21\">",
"     21",
"    </a>",
"    ]. Findings indicative of increased risk include greater magnitude of MR, flail leaflet, AF, and age &ge;50 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10,11,22\">",
"     10,11,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The magnitude of MR (quantified as the regurgitant volume or regurgitant fraction) is an important determinant of prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/22\">",
"     22",
"    </a>",
"    ]. The regurgitant volume is determined by the duration of regurgitation as well as the size of the regurgitant orifice (estimated by the effective orifice area [ERO]) and the magnitude of the systolic pressure gradient across the mitral valve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In patients with MVP, the MR may be holosystolic or mid to late systolic and thus, the duration of MR is an important variable. Thus, the ERO is a key but not sole factor affecting regurgitant volume. This distinction is one explanation for why baseline ERO predicted outcome in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/25\">",
"     25",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, there are limitations and technical challenges associated with ERO measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of ERO was suggested by a prospective study of 456 patients with isolated primary MR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/25\">",
"     25",
"    </a>",
"    ]. Eighty percent had MVP, 9 percent AF, the mean age was 63 years, the mean LVEF was 70 percent, and the mean duration of follow-up with medical therapy was 2.7 years. Clinical management proceeded according to each patient's treating physician. Cardiac surgery was eventually performed in 232 patients (51 percent) and was independently associated with increased survival (adjusted odds ratio 0.28). Quantitative grading of the severity of MR by measurement of the effective regurgitant orifice (ERO) was the most powerful predictor of outcome as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 198 patients (43 percent) with an ERO &ge;40 mm",
"      <sup>",
"       2",
"      </sup>",
"      (mean 64 mm",
"      <sup>",
"       2",
"      </sup>",
"      ) had significantly higher rates of all-cause mortality (adjusted risk ratio [RR] 2.90), cardiac death (adjusted RR 5.21), and cardiac events (adjusted RR 5.66) compared to 129 patients with an ERO &lt;20 mm",
"      <sup>",
"       2",
"      </sup>",
"      (mean 11 mm",
"      <sup>",
"       2",
"      </sup>",
"      ). The estimated rates of five-year overall mortality and cardiac mortality in the two groups were 42 versus 9 percent and 36 versus 3 percent, respectively.",
"     </li>",
"     <li>",
"      Of note, the patients with an ERO &ge;40 mm",
"      <sup>",
"       2",
"      </sup>",
"      had higher regurgitant volumes (101 versus 29",
"      <span class=\"nowrap\">",
"       mL/beat",
"      </span>",
"      with an ERO &lt;20 mm",
"      <sup>",
"       2",
"      </sup>",
"      ) as well as greater left atrial volumes, systolic pulmonary pressures, and were more likely to have MVP (98 versus 48 percent).",
"     </li>",
"     <li>",
"      Mortality rates at five years were significantly higher than expected among medically treated patients with an ERO &ge;40 mm",
"      <sup>",
"       2",
"      </sup>",
"      (42 versus 22 percent) as well as in those with an ERO of 20 to 39 mm",
"      <sup>",
"       2",
"      </sup>",
"      (34 versus 16 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, ERO was a strong predictor of outcomes in a population of patients in which ERO and regurgitation volumes were associated.",
"   </p>",
"   <p>",
"    A later study evaluating the effect of duration of regurgitation in patients with MVP found that the regurgitant volume but not ERO was a predictor of clinical outcomes (mortality, cardiac events [cardiac mortality including sudden death, heart failure, new onset atrial fibrillation], and need for mitral valve surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/22\">",
"     22",
"    </a>",
"    ]. The study compared 111 patients with mid to late systolic MR and 90 with holosystolic MR matched for age, gender, atrial fibrillation, ejection fraction and ERO. Mean regurgitant volume was substantially lower in the group with mid to late systolic MR (25 versus 49 mL), despite similar color jet areas and peak MR velocities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/22\">",
"     22",
"    </a>",
"    ]. The combined event of death or need for surgery occurred more frequently in patients with holosystolic MR than in those with mid-late systolic MR (24 versus 6 percent at one year and 44 versus 31 percent at five years). Cardiac events were also more frequent in patients with holosystolic MR (42.4 versus 15.9 percent at five years). Regurgitant volume, but not ERO, was an independent predictor of cardiac events.",
"   </p>",
"   <p>",
"    Data suggesting that prospective clinical follow-up of patients with severe MR can alter the natural history to achieve good outcomes was provided by a study of 132 asymptomatic patients with severe degenerative MR (including 58 with flail leaflet) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients were followed for 62 months and were referred for surgery at the onset of symptoms or atrial fibrillation or pulmonary hypertension or development of echocardiographic criteria for LV systolic dysfunction",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality rates at two, four, and eight years were 1, 4, and 9 percent for the entire group and 0, 5, and 8 percent for the subgroup with flail leaflet. Cumulative mortality rates were not significantly different from expected rates for either the whole group or the flail leaflet subgroup.",
"     </li>",
"     <li>",
"      Survival free of any indication for surgery at two, four, six, and eight years was 92, 78, 65, and 55 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrective surgery is indicated only in selected patients with severe chronic MR. The criteria for surgery and for monitoring of patients who do not yet meet these criteria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended the following approach to monitoring patients with MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic patients with MVP and no MR should receive follow-up clinical examinations at three to five year intervals to evaluate the likelihood of associated complications.",
"     </li>",
"     <li>",
"      Routine repeat echocardiography is not indicated in asymptomatic patients with no MR or in patients with mild MR and no change in signs or symptoms.",
"     </li>",
"     <li>",
"      Clinical evaluation and repeat echocardiography at yearly intervals in patients with high-risk findings on the initial echocardiogram (eg, diffuse thickening of the mitral leaflets and redundancy), or moderate MR.",
"     </li>",
"     <li>",
"      Clinical evaluation and repeat echocardiography every 6 to 12 months in patients with severe MR (",
"      <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the management of chronic mitral regurgitation\", section on 'Serial monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical evaluation and echocardiography at any time there is a change in signs of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe MR and signs of impaired left ventricular function should be evaluated for mitral valve surgery. Among patients who undergo mitral valve surgery, echocardiography is recommended prior to discharge or at the first postoperative visit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Noncardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with MVP who require noncardiac surgery, the perioperative cardiac risk depends upon the presence and severity of MR and left ventricular function and dimensions. Patients who do not have severe MR or left ventricular dysfunction are classified as low risk and do not require special care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse is the most common cause of MR in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. MR is usually well tolerated during pregnancy, particularly in patients with mild to moderate MR, an LVEF &gt;50 percent, and no or mild symptoms (NYHA class I or II) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ]. The normal fall in systemic vascular resistance during pregnancy improves the cardiac output, unless the regurgitation is severe. In addition, the decrease in systemic vascular resistance and increase in blood volume may improve function of the prolapsed valve and obscure the physical findings of MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link&amp;anchor=H28356962#H28356962\">",
"     \"Definition and diagnosis of mitral valve prolapse\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasional patients require beta blockers for control of palpitations or arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the generally low risk, patients with NYHA class III to IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ), an LVEF less than 40 percent, or severe pulmonary hypertension (defined as pulmonary artery pressure &gt;75 percent of systemic pressure) are considered at high maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ]. Ideally, such patients or those with severe MR who have other indications for mitral valve surgery should undergo mitral valve surgery prior to pregnancy, especially if there is a high likelihood of valve repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diuretics are warranted for the rare patient with chronic MR who develops pulmonary congestion. The risk of pulmonary congestion may be increased in women with preeclampsia because of the associated increase in systemic arterial pressure and the decline in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/30\">",
"     30",
"    </a>",
"    ]. Vasodilator therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ) should be given only for hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ]. ACE inhibitors and angiotensin II receptor blockers should be avoided during pregnancy, because of potential harm to the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=see_link\">",
"     \"Vasodilator therapy in chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic MR is also of concern when left atrial enlargement is present, since atrial fibrillation and atrial thrombi may develop with the associated need for anticoagulation and its attendant risks during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac surgery should be avoided, if possible, during pregnancy. The maternal risks are about the same as those in nonpregnant women, but cardiopulmonary bypass during pregnancy poses problems for the fetus. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H13#H13\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Cardiac surgery during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a woman with MVP presents early in pregnancy with one or more of the high risk features described above, we consider termination of pregnancy followed by corrective surgery before another attempt at pregnancy. If the mother declines termination, we manage the patient medically and, as recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, operate only for refractory NYHA class III or IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ], which may also be due to acute MR due to a ruptured chordae tendineae [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is preferable to delay surgery, if possible, until the fetus is viable; a cesarean section can then be performed as part of a combined procedure. Mitral valve repair is always preferred to valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Valve repair versus valve replacement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF FLAIL MITRAL LEAFLET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause for a flail mitral valve is ruptured chordae tendineae, often associated with MVP, endocarditis, or trauma. A less common cause is rupture of a papillary muscle in the setting of an acute myocardial infarction. Depending upon the rate and extent of chordae or papillary muscle rupture, flail mitral leaflet may result in acute, subacute or chronic MR. The course of acute MR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of flail or partial flail mitral leaflet is based upon echocardiographic evidence of a failure of leaflet coaptation with rapid systolic movement of the involved leaflet into the left atrium. In most cases, only a portion of the leaflet is disrupted and the appropriate descriptive term is partial flail leaflet (",
"    <a class=\"graphic graphic_movie graphicRef60709 \" href=\"UTD.htm?12/21/12628\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64363 \" href=\"UTD.htm?16/48/17154\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61846 \" href=\"UTD.htm?17/43/18099\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77752 \" href=\"UTD.htm?33/17/34065\">",
"     movie 8",
"    </a>",
"    ). Serious MR is usually present, as the regurgitant leak and the left ventricular (and left atrial) volume overload are more severe than in the vast majority of patients with uncomplicated MVP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link&amp;anchor=H33#H33\">",
"     \"Echocardiographic evaluation of the mitral valve\", section on 'Flail mitral valve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation may progress more rapidly in the presence of a flail leaflet than among other patients with MVP. In the study cited above of 64 patients with MVP, 10 of whom developed a new flail leaflet, there was a significantly greater rate of progression of MR in the patients with flail leaflet compared to those with stable MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/20\">",
"     20",
"    </a>",
"    ]. In the above cited study of 132 asymptomatic patients with severe degenerative MR, the 58 patients with flail leaflet tended to develop criteria for surgery slightly but not significantly earlier than those with MVP without flail [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective report evaluated the long-term (5 to 15 years) outcomes of 229 patients with flail mitral valve leaflet [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/13\">",
"     13",
"    </a>",
"    ]. Corrective surgery was performed in 62 percent while the remainder received medical therapy. The main indication for surgery was serious dyspnea (107 patients); other indications included physician preference, endocarditis, angina, and thromboembolism.",
"   </p>",
"   <p>",
"    Within 10 years of the diagnosis, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ninety percent of the patients had undergone surgery or died; risk factors for decreased survival were NYHA class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ) and a left ventricular ejection fraction &lt;60 percent (",
"      <a class=\"graphic graphic_figure graphicRef73457 \" href=\"UTD.htm?1/49/1822\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among those treated medically, the rate of cardiac mortality was 21 percent at five years and 33 percent at 10 years.",
"     </li>",
"     <li>",
"      In a multivariate analysis, mortality was markedly reduced by surgery (hazard ratio 0.29, 95 percent CI 0.15-0.56).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up review from the same authors compared the outcomes of 63 patients who had early surgery and 158 patients who were treated conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/32\">",
"     32",
"    </a>",
"    ]. Early surgery was associated with a higher rate of overall survival at 10 years (79 versus 65 percent) and a lower incidence of cardiovascular death (8 versus 29 percent), heart failure (27 versus 59 percent), and new chronic AF (4 versus 26 percent) (",
"    <a class=\"graphic graphic_figure graphicRef72108 \" href=\"UTD.htm?31/23/32126\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Later series have reported lower rates of adverse cardiac events in patients with flail leaflet, which may be due to earlier corrective surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. As an example, a study of 392 patients with flail leaflet, including 102 asymptomatic patients with LVEF &ge;60 percent, reported outcomes following 3.9 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/33\">",
"     33",
"    </a>",
"    ]. Corrective surgery was performed in 80 percent of patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five-year mortality during medical treatment was relatively low (14 percent) particularly for the subgroup of asymptomatic patients with normal left ventricular function (3 percent).",
"     </li>",
"     <li>",
"      Incidence rates during medical management of atrial fibrillation (5.4 percent per year) and heart failure (8 percent per year) were high, even in the asymptomatic, preserved LVEF subgroup (4 and 5.7 percent per year).",
"     </li>",
"     <li>",
"      Surgery was independently associated with reduced risk of death (adjusted HF 0.42, 95% CI 0.21-0.84) with benefit largely driven by MV repair. In the asymptomatic, preserved LVEF subgroup, surgery was associated with reduced risk of HF (HR 0.20, 95% CI 0.05-0.89) but the impact of surgery on mortality was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding findings can be used to develop general guidelines for the identification of patients with flail mitral valve leaflet who are at low and high risk:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival in medically treated patients presenting with normal left ventricular function and no symptoms is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, such patients are at relatively low risk although indications for surgery including atrial fibrillation (4 percent per year) and heart failure (5.7 percent per year) commonly develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     High risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients exhibiting one or more of the following factors at the time of initial diagnosis are at relatively high risk for heart failure, AF, death, or need for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/13,33\">",
"     13,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Presence of symptoms",
"     </li>",
"     <li>",
"      An LVEF &lt;60 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, the rate of development of AF in patients with flail leaflet who are in sinus rhythm is about 5 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/17\">",
"     17",
"    </a>",
"    ]. The development of AF is much less in patients who undergo early surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These low and high risk factors in patients with flail or partial flail leaflet and the rate of development of AF are similar to those in MVP cited above and chronic MR in general. As for chronic severe MR in general, management decisions for patients with flail leaflet are based largely upon the presence or absence of symptoms, the functional state of the left ventricle, as well as the feasibility of successful mitral valve repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUDDEN CARDIAC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death can occur in patients with MVP and appears to be more frequent among those with flail mitral leaflet, particularly those who are managed conservatively. Risk of sudden cardiac death in patients with MVP and flail mitral leaflet is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with chronic MR of any cause can be estimated from the history, physical examination, and echocardiography. Among patients with MVP, findings indicative of increased risk include moderate to severe MR, LVEF below 50 percent, increased end systolic diameter, increased left atrial size, AF, flail leaflet, and age &ge;50 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/10,11,17,32\">",
"     10,11,17,32",
"    </a>",
"    ]. Among patients with a flail leaflet, findings indicative of increased risk are similar: older age, symptoms, and an LVEF &lt;60 percent (",
"    <a class=\"graphic graphic_figure graphicRef73457 \" href=\"UTD.htm?1/49/1822\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6649/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/1\">",
"      Flack JM, Kvasnicka JH, Gardin JM, et al. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am Heart J 1999; 138:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/2\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/3\">",
"      Allen H, Harris A, Leatham A. Significance and prognosis of an isolated late systolic murmur: a 9- to 22-yearyearfollow-up. Br Heart J 1974; 36:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/4\">",
"      Mills P, Rose J, Hollingsworth J, et al. Long-term prognosis of mitral-valve prolapse. N Engl J Med 1977; 297:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/5\">",
"      Nishimura RA, McGoon MD, Shub C, et al. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med 1985; 313:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/6\">",
"      D&uuml;ren DR, Becker AE, Dunning AJ. Long-term follow-up of idiopathic mitral valve prolapse in 300 patients: a prospective study. J Am Coll Cardiol 1988; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/7\">",
"      Vered Z, Oren S, Rabinowitz B, et al. Mitral valve prolapse. Quantitative analysis and long-term follow-up. Isr J Med Sci 1985; 21:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/8\">",
"      Marks AR, Choong CY, Sanfilippo AJ, et al. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. N Engl J Med 1989; 320:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/9\">",
"      Avierinos JF, Detaint D, Messika-Zeitoun D, et al. Risk, determinants, and outcome implications of progression of mitral regurgitation after diagnosis of mitral valve prolapse in a single community. Am J Cardiol 2008; 101:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/10\">",
"      Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002; 106:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/11\">",
"      Zuppiroli A, Rinaldi M, Kramer-Fox R, et al. Natural history of mitral valve prolapse. Am J Cardiol 1995; 75:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/12\">",
"      Kim S, Kuroda T, Nishinaga M, et al. Relationship between severity of mitral regurgitation and prognosis of mitral valve prolapse: echocardiographic follow-up study. Am Heart J 1996; 132:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/13\">",
"      Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 1996; 335:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/14\">",
"      Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 1999; 99:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/15\">",
"      Gillinov AM, Cosgrove DM, Blackstone EH, et al. Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg 1998; 116:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/16\">",
"      Avierinos JF, Inamo J, Grigioni F, et al. Sex differences in morphology and outcomes of mitral valve prolapse. Ann Intern Med 2008; 149:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/17\">",
"      Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol 2002; 40:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/18\">",
"      Berbarie RF, Roberts WC. Frequency of atrial fibrillation in patients having mitral valve repair or replacement for pure mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 2006; 97:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/19\">",
"      Freed LA, Benjamin EJ, Levy D, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002; 40:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/20\">",
"      Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of mitral regurgitation: a prospective Doppler echocardiographic study. J Am Coll Cardiol 1999; 34:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/21\">",
"      St John Sutton M, Weyman AE. Mitral valve prolapse prevalence and complications: an ongoing dialogue. Circulation 2002; 106:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/22\">",
"      Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation 2012; 125:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/23\">",
"      Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996; 28:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/24\">",
"      Gaasch WH, Aurigemma GP. Inhibition of the renin-angiotensin system and the left ventricular adaptation to mitral regurgitation. J Am Coll Cardiol 2002; 39:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/25\">",
"      Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/26\">",
"      Otto CM, Salerno CT. Timing of surgery in asymptomatic mitral regurgitation. N Engl J Med 2005; 352:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/27\">",
"      Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006; 113:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/28\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/29\">",
"      Rayburn WF, LeMire MS, Bird JL, Buda AJ. Mitral valve prolapse. Echocardiographic changes during pregnancy. J Reprod Med 1987; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Cardiac disease in pregnancy. ACOG technical bulletin 168. 1992; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/31\">",
"      Hagay ZJ, Weissman A, Geva D, et al. Labor and delivery complicated by acute mitral regurgitation due to ruptured chordae tendineae. Am J Perinatol 1995; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/32\">",
"      Ling LH, Enriquez-Sarano M, Seward JB, et al. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation 1997; 96:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6649/abstract/33\">",
"      Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging 2008; 1:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8162 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6649=[""].join("\n");
var outline_f6_31_6649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF MITRAL VALVE PROLAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Sex differences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Development of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hemodynamic progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NATURAL HISTORY OF FLAIL MITRAL LEAFLET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - High risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUDDEN CARDIAC DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8162\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8162|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/17/34077\" title=\"figure 1\">",
"      MVP complication and MR severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/49/1822\" title=\"figure 2\">",
"      Survival in flail MV leaflet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/23/32126\" title=\"figure 3\">",
"      Early surgery flail MV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8162|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/23/32115\" title=\"movie 1\">",
"      Mitral valve prolapse four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?20/12/20672\" title=\"movie 2\">",
"      MR due to mitral valve prolapse four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/5/23646\" title=\"movie 3\">",
"      Mitral valve prolapse apical long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/32/8707\" title=\"movie 4\">",
"      Mitral valve prolapse bileaflet four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?12/21/12628\" title=\"movie 5\">",
"      Flail mitral valve four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/48/17154\" title=\"movie 6\">",
"      Flail mitral leaflet apical long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/43/18099\" title=\"movie 7\">",
"      Flail mitral leaflet apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?33/17/34065\" title=\"movie 8\">",
"      Ruptured papillary muscle post myocardial infarction long axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8162|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/34/3628\" title=\"table 1\">",
"      TTE in chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=related_link\">",
"      Vasodilator therapy in chronic mitral regurgitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6650="Neutrophil functions other than movement";
var content_f6_31_6650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neutrophil functions other than movement",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6650/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/31/6650/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/31/6650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymorphonuclear or segmented neutrophil is the last stage of full maturation of the granulocyte. The mature neutrophil is of uniform size and the nucleus is segmented into two to five lobes connected by thin chromatin strands. Neutrophils act as the first line of host cellular defense against bacterial infection and are important cellular constituents of acute inflammation, independent of etiology.",
"   </p>",
"   <p>",
"    A review of the functions of neutrophils other than those related to cellular migration is presented here. A discussion of the determinants of neutrophil migration is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERACTIONS BETWEEN MICROBES AND NEUTROPHILS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opsonization refers to the binding and alteration of the microbial surface by immunoglobulin and complement components (opsonins), thereby resulting in their recognition by specific receptors located on neutrophils. This recognition results in immune adherence, which is commonly followed by phagocytosis of the microbe. In addition to multiple mechanisms for initiation of the inflammatory response, there are regulated reactions that inhibit and ultimately shut down the process as well [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5933198\">",
"    <span class=\"h2\">",
"     Pattern recognition receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign material, such as bacteria, fungi, and parasites, display molecules that are never seen in higher organisms and are recognized by receptors globally referred to as pattern recognition receptors (PAMPs), in particular toll-like receptors. Other such receptors include the mannose receptor (CD206), CD14, scavenger receptor A (CD204), and MARCO [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5933205\">",
"    <span class=\"h2\">",
"     Apoptotic corpse receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are specific receptors that facilitate phagocytosis and removal of dead cells. These receptors recognize phosphatidylserine (TIM-1,TIM-4, BAI1, Stablin-2), Gas6 (Mer), and oxidized lipids (CD36) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OPSONINS AND OPSONIN RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal immunoglobulin opsonins are IgG1 and IgG3, while IgA1 and IgA2 also serve this function in the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ]. Dimeric complement components, C3b and C4b, provide additional opsonic function and, along with C3bi, trigger phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .) IgG and C3 correspond to the classically described \"heat stable\" and \"heat labile\" opsonins, respectively.",
"   </p>",
"   <p>",
"    Opsonins bind to the bacterial membrane, enhancing their phagocytic uptake by leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/3\">",
"     3",
"    </a>",
"    ]. In particular, the antigen binding sites (Fab) of IgG bind to the bacteria, thereby exposing the Fc binding site, the immunoglobulin region recognized by opsonic receptors.",
"   </p>",
"   <p>",
"    The Fc binding site is recognized by six classes of opsonic receptors: Fc gamma RI (CD64), Fc gamma RIIa (CD32a), Fc gamma RIIb (CD32b), Fc gamma RIIc (CD32c), Fc gamma RIIIa (CD16), Fc alpha RI (CD89), and Fc epsilon RI. In addition to these proteins, other opsonin receptors include the IgA antibody receptor or Fc alpha RI, and the complement receptors 1 (CR1) and 3 (CR3 or Mac-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fc gamma RIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fc gamma RIII, designated CD16, is constitutively expressed on the surface of neutrophils, occurring at a frequency of 100,000 to 300,000 molecules per cell. It binds IgG subclasses 1 and 3 with intermediate and low affinity, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/4\">",
"     4",
"    </a>",
"    ]. CD16 is also expressed on natural killer cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=see_link\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fc gamma RIIIA and Fc gamma RIIIB are the two genetic isoforms of Fc gamma RIII; they are structurally similar extracellularly, but differ markedly in their transmembrane and cytoplasmic domain because of alternate splicing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/5\">",
"     5",
"    </a>",
"    ]. Fc gamma IIIB, which is expressed on neutrophils, lacks both transmembrane and cytoplasmic domains; it is tethered to the cell surface by a glycosylphosphatidylinositol (GPI) protein anchor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the lack of a cytoplasmic and transmembrane protein domain, Fc gamma RIIIB is capable of triggering a signal transduction cascade; this leads to granule release but no associated respiratory burst [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, Fc gamma RIIIB, CR3, and Fc gamma RII may act synergistically to activate the respiratory burst. In a model of this interaction, ligand binding of CR3 leads to Fc gamma RII association with the actin cytoskeleton on the adherent neutrophil surface [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/8\">",
"     8",
"    </a>",
"    ]. Co-ligation of Fc gamma RIIIB results in tyrosine phosphorylation of Fc gamma RII, which serves to initiate activation of a signal transduction pathway, thereby causing the respiratory burst [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fc gamma RII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fc gamma RII, designated CD32, is a constitutive low affinity receptor, which binds dimeric but not monomeric IgG. Its expression is low (1000 to 4000 copies per cell). Fc gamma RII is considered a low affinity receptor with the following subclass affinities: IgG1 = IgG3 &gt;&gt; IgG2 = IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fc gamma RII-mediated signaling requires the activation of tyrosine kinases of both Src-family kinases and Syk, resulting in tyrosine phosphorylation of Shc, activation of phospholipase C, and increased intracellular calcium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, Fc gamma RII engagement leads to mitogen-activated protein (MAP) kinase phosphorylation and activation, a necessary prerequisite for phagocytosis.",
"   </p>",
"   <p>",
"    In addition to promoting phagocytosis, the cytoplasmic domain of Fc gamma RII may play an important role in fusion of phagosomes with lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/11\">",
"     11",
"    </a>",
"    ]. A mutant Fc gamma RII that lacks tyrosine phosphorylation sites can still mediate phagolysosome formation. Fc gamma RII also appears to be a receptor for C-reactive protein, an acute phase protein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fc gamma RI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fc gamma RI, designated CD64, is not expressed on quiescent neutrophils or cells in their basal state, but is found at 15,000 to 25,000 copies after such cells are exposed to interferon gamma (IFNg) (but not to IFN-alpha or beta). Other cytokines, such as granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), do not induce expression of Fc gamma RI in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/13\">",
"     13",
"    </a>",
"    ]. The protein is a single transmembrane protein receptor that binds IgG1 and IgG3 with high affinity, promoting phagocytosis of particles or bacteria opsonized with IgG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     IgA antibody receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymeric IgA antibody can function as an opsonin; it is recognized on neutrophils by Fc alpha R [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/14\">",
"     14",
"    </a>",
"    ]. Fc alphaR, designed CD89, is a 60 kD protein composed of two immunoglobulin-like domains that share homology with Fc gamma R. Fc alpha R mediates signal transduction via G-protein linked phospholipase C activation, leading to phagocytosis and stimulation of the respiratory burst [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2,15-17\">",
"     2,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complement receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opsonic phagocytosis also involves complement components. C3 is bound covalently on microbes by prior-bound IgG or IgM activation of the classical pathway, or by antibody-independent activation of the alternative pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CR1",
"      </strong>",
"      &mdash; With complement activation, C3 is proteolytically converted to C3b; this fragment remains covalently bound to the microbe and is recognized by neutrophils via complement receptor type 1 (CR1) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"       \"Regulators and receptors of the complement system\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      CR1 (CD 35) binds dimeric C3b with an affinity of 0.5 nM. Although the binding affinity is low, neutrophils effectively phagocytize microbes or particles opsonized with C3b because they are coated with a high density of C3b molecules. CR1 also functions as a co-factor in the breakdown of its ligand C3dg, preventing the accumulation of C3bi [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. When C3b is generated by IgG or IgM, it is labile and is converted to the more stable ligand C3bi; by comparison, C3b is more stable as an opsonin when its generation occurs via the alternative pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"       \"Complement pathways\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       CR3",
"      </strong>",
"      &mdash; The clustering of C3b and C3bi on the microbe is similar to the clustering of CR3, the receptor for C3bi, on neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. CR3 recognizes C3bi but not C3b, and the binding requires multimers of C3bi.",
"      <br/>",
"      <br/>",
"      In contrast to the other opsonic receptors (such as CR1, Fc gamma RII, Fc gamma RIII), CR3 requires high but physiologic concentrations of divalent cation (approximately 0.5 mM of calcium and magnesium) for effective ligand binding [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/25\">",
"       25",
"      </a>",
"      ]. CR3, designated",
"      <span class=\"nowrap\">",
"       CD11b/CD18,",
"      </span>",
"      is a beta 2 integrin family member and is composed of two polypeptide chains, an alpha subunit of 185 Kd and a beta subunit of 95 kD. Both chains have been cloned and sequenced. Binding of CR3 to C3bi is enhanced one hundred fold by an amphipathic anion lipid [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/26\">",
"       26",
"      </a>",
"      ], or by phosphorylation or aggregation of CR3 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/24,27,28\">",
"       24,27,28",
"      </a>",
"      ]. Although CR3 binding does not directly trigger the respiratory burst [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/29,30\">",
"       29,30",
"      </a>",
"      ], it plays a critical role in adherence-dependent potentiation of the respiratory burst and secretory responses of neutrophils (see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"       \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     C1q receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1q, the recognition subunit of the classical complement pathway, interacts with specific neutrophil surface molecules to trigger the respiratory burst [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The affinity as well as the density of the receptors on the cell surface determine binding to these receptors. This signaling is mediated through Rap1 that in turn results in conformational changes in the external domains of integrin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21345347\">",
"    <span class=\"h1\">",
"     PHAGOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The motile responses of neutrophils to microbial infection include emigration out of the vasculature and movement toward the source of the inflammatory chemoattractant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    .) This culminates in the phagocytic ingestion of opsonized microbes.",
"   </p>",
"   <p>",
"    Engulfment occurs via the advancing pseudopod as the neutrophil surrounds the microbe. The arms of the pseudopod fuse their distal membranes, thereby sealing the microbe into a membrane-lined vacuole. The pseudopods are rich in actin, which is required for this action. In addition, signals from the cytoplasm arising from specific ligand receptors direct actin filaments directly beneath the zone in contact with the microbe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/35\">",
"     35",
"    </a>",
"    ]. The pseudopod's receptors engage a continuous distribution of specific opsonic ligands, thereby assuring their confinement in the phagocytic vacuole [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/36\">",
"     36",
"    </a>",
"    ]. Binding to the Fc receptors results in receptor clustering, as bivalent or multivalent ligands are required to activate the signaling cascade. The cytosolic domain of these receptors has a region known as the immuno-receptor tyrosine-based activation motif (ITAM) that is the substrate for phosphorylation by src kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DEGRANULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Degranulation of neutrophils begins simultaneously with the onset of phagocytosis. The granules translocate and ultimately fuse their membranes with the newly created phagocytic vacuoles formed from invaginations of the plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microbial killing and digestion subsequently takes place within these phagolysosomes; however, granule contents secreted extracellularly inflict tissue injury as well as kill undigested microbes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1,2,37,38\">",
"     1,2,37,38",
"    </a>",
"    ]. Degranulation also occurs when neutrophils adhere to tissue surfaces and then bind immune complexes, aggregated immunoglobulin, complement components, or certain cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. Under these conditions, granule content release occurs by a process of reverse endocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/45\">",
"     45",
"    </a>",
"    ] or frustrated phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/41\">",
"     41",
"    </a>",
"    ]. Granules fuse with the plasma membrane, thereby discharging their contents directly outside of the cell.",
"   </p>",
"   <p>",
"    There are different types of neutrophilic granules with varying properties. Specific granules discharge more rapidly than do primary granules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1,2,46\">",
"     1,2,46",
"    </a>",
"    ], and more of their contents are secreted extracellularly, perhaps through incompletely formed phagosomes. Primary azurophilic granules are most analogous to lysosomes since they contain all the acid hydrolases found in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acidic environment of the phagolysosome creates a pH optimum for enzyme function and essential for further degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Blockade of anion channels impairs ion fluxes of sodium and hydrogen and prevents degranulation in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/50\">",
"     50",
"    </a>",
"    ]; by comparison, alkalinization of granules promotes their secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Degranulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    membrane fusion requires and is regulated by an additional number of cytoplasmic proteins and physiologic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytoskeletal proteins are essential for degranulation. These proteins facilitate granule translocation to either the phagolysosome or to the plasma membrane. Both microtubules and microfilaments are involved. Granules bind to polymerized microtubules within 30 seconds of activation of neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/52\">",
"       52",
"      </a>",
"      ]. If microtubule polymerization is inhibited, degranulation is blocked [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/50,53\">",
"       50,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Membrane fusion likely involves activation of several calcium sensitive neutrophil phospholipases, thereby resulting in altered lipid composition of granule-phagosome or granule-plasma membrane contact points. As an example, phospholipase A2 promotes fusion of complex liposomes similar in composition to neutrophil plasma membrane by lowering the calcium requirement to achieve fusion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The concentration of free cytosolic calcium required for exocytosis of primary, specific, tertiary, and secretory vesicles varies. Secretory vesicles are exceptionally sensitive to very small increments in cytosolic free calcium, whereas primary granules require the highest concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nucleotide receptors help regulate these processes as Mg-ATP and varying concentrations of other trinucleotides stimulate degranulation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]; primary granules contain two GTP binding proteins, and specific granules and plasma membranes contain a set of three GTP binding proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of adenosine blocks degranulation and the respiratory burst, thereby supporting a regulatory role for adenosine receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/59-61\">",
"       59-61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Annexin I and II are two of several proteins which promote fusion between phospholipid vesicles and the cytoplasmic surface of neutrophil membranes. Intact neutrophil or neutrophil membrane preps treated with trypsin do not bind to liposomes enriched with fusogenic lipids, thereby supporting a role in degranulation for cytoplasmic plasma membrane proteins, such as annexin I [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two isoforms of another fusogenic protein, synaptosomal-associated protein of 25 kD size (SNAP-25) are present in neutrophils. SNAP is essential for exocytosis at nerve terminals [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/64\">",
"       64",
"      </a>",
"      ]. Other proteins functioning in the docking and fusion of synaptic vesicles at the plasma membrane and identified in neutrophils are secretory vesicle-associated membrane protein-2 (VAMP-2), syntaxin 4, and SCAMP. The latter protein is also found in gelatinase, specific and azurophilic granules as well as the secretory vesicles of neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Secretagogues are soluble molecules which activate neutrophils and provoke the release of granule contents to the outside of the cell. Complete secretagogues induce the release of both primary and specific granules and elicit a transient rise in Ca+2i and cyclic AMP. Incomplete secretagogues cause a rise in Ca+2i and induce release of specific granules without altering cyclic AMP levels [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most chemotactic factors are complete secretagogues; incomplete secretagogues include phorbol myristate acetate (PMA) and the cell surface reactive lectin concanavalin A (Con A). In addition, several non-chemotactic interleukins, cytokines, and bone marrow growth factors act either as complete or incomplete secretagogues. These include TNF-alpha, interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-4 (IL-4) and -8 (IL-8), and granulocyte macrophage colony-stimulating factor (GM-CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/67-73\">",
"     67-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SIGNAL TRANSDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory mediators stimulate neutrophils in a dose dependent manner by activating a specific subfamily of intracellular G-proteins. All G-proteins are composed of three subunits (alpha, beta, and gamma) and are classified according to their alpha subunit. G-proteins that stimulate adenylyl cyclase are classified as the Gs type; those that inhibit adenylyl cyclase are called Gi. The alpha subunit confers specificity for each receptor, binds guanine nucleotide, and serves as the potential substrate for pertussis toxin-catalyzed ADP ribosylation. Within neutrophils, all inflammatory mediators stimulate Gi proteins.",
"   </p>",
"   <p>",
"    Each chemoattractant or chemokine binds to one or several seven transmembrane domain receptor(s) on the surface of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    .) These receptors are coupled to the pertussis-toxin-sensitive Gi protein to transduce a cascade of metabolic reactions which, in turn, initiate a diverse set of cellular reactions. These include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shape changes",
"     </li>",
"     <li>",
"      Increased adherence",
"     </li>",
"     <li>",
"      Chemokinesis and chemotaxis",
"     </li>",
"     <li>",
"      Phagocytic ingestion",
"     </li>",
"     <li>",
"      Initiation of the respiratory burst",
"     </li>",
"     <li>",
"      Granule secretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Molecular mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following chemoattractant receptor occupation, G-protein subunits cause activation of enzymes or other proteins, ultimately resulting in a variety of cellular responses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1,74\">",
"     1,74",
"    </a>",
"    ]. These enzymes, such as adenylyl cyclase or phospholipase C, generate specific second messengers, including cyclic adenosine monophosphate (cAMP) and inositol 1,4,5 triphosphate (IP3) and diacylglycerol (DAG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Phospholipases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific binding of a neutrophil chemokine receptor by the appropriate ligand activates a phosphoinositide-specific phospholipase C; this subsequently generates two second messengers, IP3 and DAG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. IP3 induces the release of calcium from intracellular storage organelles (calciosomes), thereby leading to a transient rise in cytosolic free calcium (Ca2i) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"     2",
"    </a>",
"    ]. Ca2i potentiates neutrophil degranulation and superoxide anion generation. Diacylglycerol remains associated with the membrane and participates in the activation of protein kinase C (see below).",
"   </p>",
"   <p>",
"    Activation of Phospholipase D follows activation of Phospholipase C [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Phospholipase D acts on phosphatidylcholine (PC) to generate phosphatidic acid which gives rise to diradylglycerides. Diradylglycerol generated by phospholipase D plays an important role in degranulation and activation of the respiratory burst in adherent neutrophil.",
"   </p>",
"   <p>",
"    A third phospholipase, phospholipase A2, is activated in neutrophils and provides the source for generation of arachidonic acid and lysophosphatidic acid from phosphatidic acid. Arachidonate and lysophosphatidic acid are subsequently lipoxygenated and acylated to LTB4 and PAF, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/80\">",
"     80",
"    </a>",
"    ]. Since only a small proportion of arachidonic acid is metabolized through cyclooxygenase in the neutrophil, its function is not affected by treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Kinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein kinase C translocates from cytosol to membrane upon activation by Ca2i; this leads to phosphorylation of serine and threonine residues of a variety of proteins. Protein phosphorylation markedly changes the charge and conformation of the proteins, thereby resulting in altered enzyme activity and protein binding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophils, which are adherent to endothelium or other surfaces and subsequently activated by chemotactic agonists, undergo tyrosine phosphorylation of proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. The activation of tyrosine kinases therefore involves beta-2 integrins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], and the activation of chemokine or non-chemotactic inflammatory mediator receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/87-90\">",
"     87-90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adenosine and adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine and adrenergic agonists attenuate neutrophil activation by binding to specific adenosine A2 and beta-adrenergic receptors, which uncouples chemotactic receptors from Gi2-proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/91\">",
"     91",
"    </a>",
"    ]. The signal for this response proceeds via a novel pathway, which involves a",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    protein phosphatase in the plasma membrane but is independent of c-AMP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/92\">",
"     92",
"    </a>",
"    ]. On the other hand, adenosine nucleotides, including extracellular ATP, bind to specific sites and activate signal transduction independent of ATP hydrolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils exist in one of three states: quiescent, activated, or primed. Primed neutrophils are poised to undergo an exaggerated respiratory burst or secretory response when specific receptors are triggered.",
"   </p>",
"   <p>",
"    Three main types of agonists are capable of priming neutrophils:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory mediators that are chemotactic and bind to the seven transmembrane domain family of receptors.",
"     </li>",
"     <li>",
"      Serum immunoglobulin and complement opsonins that bind to single transmembrane receptors and require cross-linking for full activation.",
"     </li>",
"     <li>",
"      Inflammatory cytokines and bone marrow growth factors that bind to specific single transmembrane receptors. These include tumor necrosis factor alpha (TNF-alpha), lipopolysaccharide (LPS), peptidoglycan derived from normal bacterial flora in the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/94\">",
"       94",
"      </a>",
"      ], granulocyte-monocyte colony stimulating factor (GM-CSF), granulocyte colony stimulation factor (G-CSF), substance P, orthovanadate, and interleukin-1 (IL-1). These molecules prime at dose levels that do not elicit a rise of cytosolic free Ca++ but lead to intracellular protein phosphorylation of tyrosine residues [",
"      <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/95,96\">",
"       95,96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Priming results from intracellular \"crosstalk\" between the calcium signaling system acting via",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases (such as a protein kinase C, phospholipase A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/97\">",
"     97",
"    </a>",
"    ] or calmodulin-dependent kinases) and the calcium independent tyrosine kinase signaling system acting via tyrosine kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/95\">",
"     95",
"    </a>",
"    ], which leads to recruitment of secretory membranes containing cytochrome b, a component of the NADPH oxidase, to the plasma membrane. The end result is complete phosphorylation of those proteins involved in achieving an exaggerated respiratory burst and degranulation response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of any of the three classes of receptors subsequently primes the neutrophil for an exaggerated respiratory burst",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secretory response. However, only the chemotactic and opsonic phagocytic receptors can trigger the exaggerated response when engaged by a higher dose level of the appropriate agonist.",
"   </p>",
"   <p>",
"    Neutrophils can be primed by one agonist and then triggered into the exaggerated response by a second [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/98\">",
"     98",
"    </a>",
"    ]. Priming can also occur through either high or low affinity receptors of the same receptor class. In addition, the primed neutrophil can be challenged with either a higher dose of the same agonist used for priming or a second agonist ligating to a different receptor.",
"   </p>",
"   <p>",
"    Depending upon the nature of the stimulus, priming may be achieved rapidly over a few minutes or more slowly over 30 minutes. The primed state is transient, lasting up to several hours in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/95,99\">",
"     95,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MICROBE KILLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils destroy microbes and possibly damage surrounding tissue via multiple pathways, including oxidative killing associated with the respiratory burst, as well as non-oxidative related killing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Respiratory burst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophil activation leads within seconds to a dramatic increase in oxygen consumption, which is unaffected by mitochondrial poisons [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/100\">",
"     100",
"    </a>",
"    ]. This respiratory burst results in microbe killing and, occasionally, tissue damage.",
"   </p>",
"   <p>",
"    The source of reducing equivalents for the respiratory burst oxidase and the glutathione detoxification pathway is NADPH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1,2,101-103\">",
"     1,2,101-103",
"    </a>",
"    ]; this compound is replenished from NADP by glucose-6-phosphate dehydrogenase in the hexose monophosphate shunt (G6PD) (",
"    <a class=\"graphic graphic_figure graphicRef79524 \" href=\"UTD.htm?7/59/8126\">",
"     figure 1",
"    </a>",
"    ). The NADPH oxidase is a multicomponent enzyme system composed of at least seven distinct proteins located in various regions of the quiescent neutrophil. Some of these proteins translocate to the cortical cytoskeleton and membrane of the phagolysosome or plasma membrane during opsonic phagocytosis or secretagogue activation of the neutrophil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Oxidative killing and signalling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The products of the respiratory burst, which are generated by single electron transfer from NADPH to molecular oxygen, form superoxide anion. Subsequently, superoxide rapidly dismutates either enzymatically (by superoxide dismutase) or spontaneously to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . Hydrogen peroxide reacts with superoxide anion, forming highly reactive hydroxyl radical, and (with chloride ion) hypochlorous acid.",
"   </p>",
"   <p>",
"    These products are bactericidal to varying degrees. Superoxide anion is only weakly bactericidal, whereas hydroxyl radical kills microbes and injures surrounding tissue. Hypochlorous acid forms longer lasting chloramines, which may contribute to oxidative killing. More importantly these molecules lead to degranulation and activation of granule proteases, such as elastase, collagenase, and cathepsin, which lead to destruction of microorganisms and damage to surrounding tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another mechanism that increases the potency of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    is a reaction with ferrous iron to form hydroxyl radical. Within neutrophils, hydroxyl radical may be formed by the reaction of hydrogen peroxide and superoxide anion, thereby yielding molecular oxygen plus OH- and toxic hydroxyl radical (Haber-Weiss reaction) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of oxidative killing in normal host defense can be observed in patients with chronic granulomatous disease. This is a group of syndromes that share a defect in a component of the phagocyte NADPH-oxidase complex [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/1,107-109\">",
"     1,107-109",
"    </a>",
"    ]. Without this enzyme activity, phagocytic cells cannot produce superoxide, peroxide, and other potent microbicidal radicals, and are less able to kill ingested pathogens, thereby resulting in severe infections of the lungs, skin, sinuses, and lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nitric oxide pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;A microbicidal pathway that is independent of neutrophil phagocytic oxidase is the generation of reactive nitrogen intermediates via nitric oxide synthase (NOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/111\">",
"     111",
"    </a>",
"    ]. Nitric oxide (NO) or other labile NO intermediates derived from L-arginine are induced in neutrophils exposed to mediators of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In addition, superoxide dismutase (SOD) enhances the inhibition of thrombin-induced platelet aggregation by release of NADPH, tetrahydro biopterin and FAD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating neutrophils display very low NOS activity due, in part, to an endogenous inhibitor to constitutive NOS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/115\">",
"     115",
"    </a>",
"    ]. Although NOS colocalizes to the primary granule of neutrophils, the release of nitric oxide intermediates from neutrophils is not associated with either degranulation or the respiratory burst [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. Three isoforms of NOS occur in blood cells; NOS I in neutrophils, NOS II in eosinophils and NOS III in platelets and megakaryocytes. NOS II isoform is inducible in neutrophils to almost 50-fold by gram negative bacterial endotoxins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/118,119\">",
"     118,119",
"    </a>",
"    ], and likely plays the major role in neutrophil NO- related inflammatory responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Non-oxidative microbicidal killing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils can also kill bacteria utilizing microbicidal proteins present in the matrix of primary azurophilic granules and to a lesser extent in specific and gelatinase granules. The oxidase cytochrome components are stored in the membrane of specific and gelatinase granules and in secretory vesicles (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most important non-oxidative antimicrobial proteins of neutrophils are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/107,120,121\">",
"     107,120,121",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Defensins",
"     </li>",
"     <li>",
"      Serprocidins, including cathepsin G and azurocidin (GAP 37)",
"     </li>",
"     <li>",
"      Bacterial permeability-increasing protein (BPI)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Defensins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defensins constitute as much as 50 percent of the protein content of neutrophil granules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/122\">",
"     122",
"    </a>",
"    ]. They kill microbes by inserting into hydrophobic channels, thereby forming voltage-dependent ion channels in lipid bilayers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Serprocidins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cathepsin G is a serine protease that kills both gram positive and gram negative bacteria by binding to penicillin-binding proteins of bacteria (such as Staphylococcus aureus); this interferes with the synthesis of peptidoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/124\">",
"     124",
"    </a>",
"    ]. Azurocidin is another serine proteinase that kills Escherichia coli, Streptococcus faecalis and Candida albicans at acidic pH as achievable in the phagolysosomes of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Bacterial permeability-increasing protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPI protein kills gram negative bacteria by binding to their lipopolysaccharide capsule and altering their bacterial membrane to extracellular solutes. A mutant strain of Salmonella typhimurium that is resistant to BPI protein was also found to be resistant to neutrophil bactericidal activity under strict anaerobic conditions, thereby pointing to the clinical importance of BPI protein in non-oxidative killing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific granule marker lactoferrin is bactericidal to some gram negative bacteria by generating free radicals from iron. Lysozyme, which is present in azurophil or primary specific and gelatinase granules, probably aides in the digestion of killed bacteria after they have had their capsule altered by both oxidative and non-oxidative mechanisms within phagolysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5933783\">",
"    <span class=\"h2\">",
"     Neutrophil extracellular traps (NETS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils can continue to participate in antimicrobial activity even after they undergo apoptosis. During neutrophil cell death, the nuclei swell, chromatin dissolves and large strands of decondensed DNA extrude from the cell carrying with them proteins from cytosol, granules, and histones from the nuclei themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. While these NETs entrap bacteria, they do not appear to be bacteriocidal, since entrapped",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    bacteria and",
"    <em>",
"     Candida albicans",
"    </em>",
"    blastospores could be released from the NETs and recovered in cell medium following incubation with DNase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NET formation is dependent on",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , and thus patients with chronic granulomatous disease and with myeloperoxidase deficiency do not form NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. Additionally, normal newborns are partially deficient in ability to form NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/31/6650/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20917272\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymorphonuclear or segmented neutrophils act as the first line of host cellular defense against bacterial infection and are important cellular constituents of acute inflammation. Their migration function in response to chemoattractants, not described here, localizes them to sites of infection or inflammation, following which they exert the following functions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reaction with opsonin-coated invading organisms",
"     </li>",
"     <li>",
"      Engulfment",
"     </li>",
"     <li>",
"      Formation of phagocytic vacuoles",
"     </li>",
"     <li>",
"      Degranulation and activation",
"     </li>",
"     <li>",
"      Microbial killing through oxidative and non-oxidative mechanisms",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/1\">",
"      Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010; 33:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/2\">",
"      Flannagan RS, Jaumouill&eacute; V, Grinstein S. The cell biology of phagocytosis. Annu Rev Pathol 2012; 7:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/3\">",
"      Wright AE, Douglas SR. An experimental investigation of the role of the body fluids in connection with phagocytosis. Proc R Soc Lond 1903; 72:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/4\">",
"      Kurlander RJ, Batker J. The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes. J Clin Invest 1982; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/5\">",
"      Scallon BJ, Scigliano E, Freedman VH, et al. A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms. Proc Natl Acad Sci U S A 1989; 86:5079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/6\">",
"      Edberg JC, Salmon JE, Kimberly RP. Functional capacity of Fc gamma receptor III (CD16) on human neutrophils. Immunol Res 1992; 11:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/7\">",
"      Huizinga TW, Dolman KM, van der Linden NJ, et al. Phosphatidylinositol-linked FcRIII mediates exocytosis of neutrophil granule proteins, but does not mediate initiation of the respiratory burst. J Immunol 1990; 144:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/8\">",
"      Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol 1994; 125:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/9\">",
"      Karas SP, Rosse WF, Kurlander RJ. Characterization of the IgG-Fc receptor on human platelets. Blood 1982; 60:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/10\">",
"      Unkeless JC, Shen Z, Lin CW, DeBeus E. Function of human Fc gamma RIIA and Fc gamma RIIIB. Semin Immunol 1995; 7:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/11\">",
"      Worth RG, Mayo-Bond L, Kim MK, et al. The cytoplasmic domain of FcgammaRIIA (CD32) participates in phagolysosome formation. Blood 2001; 98:3429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/12\">",
"      Bharadwaj D, Stein MP, Volzer M, et al. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 1999; 190:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/13\">",
"      Huizinga TW, Roos D, von dem Borne AE. Neutrophil Fc-gamma receptors: a two-way bridge in the immune system. Blood 1990; 75:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/14\">",
"      Shen L. A monoclonal antibody specific for immunoglobulin A receptor triggers polymorphonuclear neutrophil superoxide release. J Leukoc Biol 1992; 51:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/15\">",
"      Shen L, Lasser R, Fanger MW. My 43, a monoclonal antibody that reacts with human myeloid cells inhibits monocyte IgA binding and triggers function. J Immunol 1989; 143:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/16\">",
"      Fargeas CA, Scholler M, Pini A, et al. Purification and partial characterization of rat macrophage Fc receptor and binding factor for IgA. Biochim Biophys Acta 1990; 1037:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/17\">",
"      Maliszewski CR, March CJ, Schoenborn MA, et al. Expression cloning of a human Fc receptor for IgA. J Exp Med 1990; 172:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/18\">",
"      Law SK, Levine RP. Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci U S A 1977; 74:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/19\">",
"      Sim RB, Twose TM, Paterson DS, Sim E. The covalent-binding reaction of complement component C3. Biochem J 1981; 193:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/20\">",
"      Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981; 153:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/21\">",
"      Medof ME, Iida K, Mold C, Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 1982; 156:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/22\">",
"      Newman SL, Mikus LK. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3. J Exp Med 1985; 161:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/23\">",
"      Hermanowski-Vosatka A, Detmers PA, G&ouml;tze O, et al. Clustering of ligand on the surface of a particle enhances adhesion to receptor-bearing cells. J Biol Chem 1988; 263:17822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/24\">",
"      Detmers PA, Wright SD, Olsen E, et al. Aggregation of complement receptors on human neutrophils in the absence of ligand. J Cell Biol 1987; 105:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/25\">",
"      Wright SD, Silverstein SC. Tumor-promoting phorbol esters stimulate C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes. J Exp Med 1982; 156:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/26\">",
"      Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 1990; 110:529.",
"     </a>",
"    </li>",
"    <li>",
"     Wright SD. Receptors for complement and the biology of phagocytosis. In: Inflammation: Basic Principles and Clinical Correlates, 2nd ed, Gallin JI, Goldstein IM, Snyderman R (Eds), Raven Press, New York 1992. p.477.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/28\">",
"      Chatila TA, Geha RS, Arnaout MA. Constitutive and stimulus-induced phosphorylation of CD11/CD18 leukocyte adhesion molecules. J Cell Biol 1989; 109:3435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/29\">",
"      Yamamoto K, Johnston RB Jr. Dissociation of phagocytosis from stimulation of the oxidative metabolic burst in macrophages. J Exp Med 1984; 159:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/30\">",
"      Aderem AA, Wright SD, Silverstein SC, Cohn ZA. Ligated complement receptors do not activate the arachidonic acid cascade in resident peritoneal macrophages. J Exp Med 1985; 161:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/31\">",
"      Nathan CF. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987; 80:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/32\">",
"      Nathan C, Srimal S, Farber C, et al. Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol 1989; 109:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/33\">",
"      Lowell CA, Berton G. Integrin signal transduction in myeloid leukocytes. J Leukoc Biol 1999; 65:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/34\">",
"      Ruiz S, Henschen-Edman AH, Tenner AJ. Localization of the site on the complement component C1q required for the stimulation of neutrophil superoxide production. J Biol Chem 1995; 270:30627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/35\">",
"      Moffat FL Jr, Han T, Li ZM, et al. Involvement of CD44 and the cytoskeletal linker protein ankyrin in human neutrophil bacterial phagocytosis. J Cell Physiol 1996; 168:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/36\">",
"      Griffin FM Jr, Silverstein SC. Segmental response of the macrophage plasma membrane to a phagocytic stimulus. J Exp Med 1974; 139:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/37\">",
"      Goldstein IM. Polymorphonuclear Leukocyte lysosomes and immune tissue injury. Prog Allergy 1976; 20:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/38\">",
"      Weissmann G. Activation of neutrophils and the lesions of rheumatoid arthritis. J Lab Clin Med 1982; 100:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/39\">",
"      Henson PM. Interaction of cells with immune complexes: adherence, release of constituents, and tissue injury. J Exp Med 1971; 134:114s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/40\">",
"      Henson PM. The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. J Immunol 1971; 107:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/41\">",
"      Henson PM, Oades ZG. Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose. J Clin Invest 1975; 56:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/42\">",
"      Henson PM, Johnson HB, Spiegelberg HL. The release of granule enzymes from human neutrophils stimulated by aggregated immunoglobulins of different classes and subclasses. J Immunol 1972; 109:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/43\">",
"      Hawkins D. Neutrophilic leukocytes in immunologic reactions: evidence for the selective release of lysosomal constituents. J Immunol 1972; 108:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/44\">",
"      Becker EL, Showell HJ. The ability of chemotactic factors to induce lysosomal enzyme release. II. The mechanism of release. J Immunol 1974; 112:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/45\">",
"      Weissmann G, Zurier RB, Spieler PJ, Goldstein IM. Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med 1971; 134:149s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/46\">",
"      Bainton DF. Sequential degranulation of the two types of polymorphonuclear leukocyte granules during phagocytosis of microorganisms. J Cell Biol 1973; 58:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/47\">",
"      Wright DG. Human neutrophil degranulation. Methods Enzymol 1988; 162:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/48\">",
"      Klempner MS, Styrt B. Alkalinizing the intralysosomal pH inhibits degranulation of human neutrophils. J Clin Invest 1983; 72:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/49\">",
"      Wright J, Schwartz JH, Olson R, et al. Proton secretion by the sodium/hydrogen ion antiporter in the human neutrophil. J Clin Invest 1986; 77:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/50\">",
"      Mollinedo F, Nieto JM, Andreu JM. Cytoplasmic microtubules in human neutrophil degranulation: reversible inhibition by the colchicine analogue 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1- one. Mol Pharmacol 1989; 36:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/51\">",
"      Tapper H. The secretion of preformed granules by macrophages and neutrophils. J Leukoc Biol 1996; 59:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/52\">",
"      Rothwell SW, Nath J, Wright DG. Interactions of cytoplasmic granules with microtubules in human neutrophils. J Cell Biol 1989; 108:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/53\">",
"      Jackson JK, Tudan C, Sahl B, et al. Calcium pyrophosphate dihydrate crystals activate MAP kinase in human neutrophils: inhibition of MAP kinase, oxidase activation and degranulation responses of neutrophils by taxol. Immunology 1997; 90:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/54\">",
"      Blackwood RA, Transue AT, Harsh DM, et al. PLA2 promotes fusion between PMN-specific granules and complex liposomes. J Leukoc Biol 1996; 59:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/55\">",
"      Sengel&oslash;v H, Kjeldsen L, Borregaard N. Control of exocytosis in early neutrophil activation. J Immunol 1993; 150:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/56\">",
"      Smolen JE, Sandborg RR. Ca2(+)-induced secretion by electropermeabilized human neutrophils. The roles of Ca2+, nucleotides and protein kinase C. Biochim Biophys Acta 1990; 1052:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/57\">",
"      O'Flaherty JT, Cordes JF. Human neutrophil degranulation responses to nucleotides. Lab Invest 1994; 70:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/58\">",
"      Philips MR, Abramson SB, Kolasinski SL, et al. Low molecular weight GTP-binding proteins in human neutrophil granule membranes. J Biol Chem 1991; 266:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/59\">",
"      Schrier DJ, Imre KM. The effects of adenosine agonists on human neutrophil function. J Immunol 1986; 137:3284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/60\">",
"      Bouma MG, Jeunhomme TM, Boyle DL, et al. Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol 1997; 158:5400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/61\">",
"      Richter J. Effect of adenosine analogues and cAMP-raising agents on TNF-, GM-CSF-, and chemotactic peptide-induced degranulation in single adherent neutrophils. J Leukoc Biol 1992; 51:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/62\">",
"      Oshry L, Meers P, Mealy T, Tauber AI. Annexin-mediated membrane fusion of human neutrophil plasma membranes and phospholipid vesicles. Biochim Biophys Acta 1991; 1066:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/63\">",
"      Blackwood RA, Hessler RJ. Effect of calcium on phenothiazine inhibition of neutrophil degranulation. J Leukoc Biol 1995; 58:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/64\">",
"      Mollinedo F, Lazo PA. Identification of two isoforms of the vesicle-membrane fusion protein SNAP-23 in human neutrophils and HL-60 cells. Biochem Biophys Res Commun 1997; 231:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/65\">",
"      Brumell JH, Volchuk A, Sengelov H, et al. Subcellular distribution of docking/fusion proteins in neutrophils, secretory cells with multiple exocytic compartments. J Immunol 1995; 155:5750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/66\">",
"      Smolen JE, Weissmann G. Stimuli which provoke secretion of azurophil enzymes from human neutrophils induce increments in adenosine cyclic 3'-5'-monophosphate. Biochim Biophys Acta 1981; 672:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/67\">",
"      Smith RJ, Bowman BJ, Speziale SC. Interleukin-1 stimulates granule exocytosis from human neutrophils. Int J Immunopharmacol 1986; 8:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/68\">",
"      Smith RJ, Speziale SC, Bowman BJ. Properties of interleukin-1 as a complete secretagogue for human neutrophils. Biochem Biophys Res Commun 1985; 130:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/69\">",
"      Bank U, Reinhold D, Kunz D, et al. Effects of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) on neutrophil elastase release. Inflammation 1995; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/70\">",
"      Borish L, Rosenbaum R, Albury L, Clark S. Activation of neutrophils by recombinant interleukin 6. Cell Immunol 1989; 121:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/71\">",
"      Richter J, Andersson T, Olsson I. Effect of tumor necrosis factor and granulocyte/macrophage colony-stimulating factor on neutrophil degranulation. J Immunol 1989; 142:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/72\">",
"      Goldstein IM. Neutrophil degranulation. In: Contemporary Topics in Immunobiology 1984; 14:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/73\">",
"      Mollinedo F, Schneider DL. Intracellular organelle motility and membrane fusion processes in human neutrophils upon cell activation. FEBS Lett 1987; 217:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/74\">",
"      Wells TN, Power CA, Proudfoot AE. Definition, function and pathophysiological significance of chemokine receptors. Trends Pharmacol Sci 1998; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/75\">",
"      Dougherty RW, Godfrey PP, Hoyle PC, et al. Secretagogue-induced phosphoinositide metabolism in human leucocytes. Biochem J 1984; 222:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/76\">",
"      Dillon SB, Murray JJ, Verghese MW, Snyderman R. Regulation of inositol phosphate metabolism in chemoattractant-stimulated human polymorphonuclear leukocytes. Definition of distinct dephosphorylation pathways for IP3 isomers. J Biol Chem 1987; 262:11546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/77\">",
"      Andersson T, Schlegel W, Monod A, et al. Leukotriene B4 stimulation of phagocytes results in the formation of inositol 1,4,5-trisphosphate. A second messenger for Ca2+ mobilization. Biochem J 1986; 240:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/78\">",
"      Billah MM, Anthes JC. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J 1990; 269:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/79\">",
"      Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J 1991; 5:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/80\">",
"      Thelen M, Rosen A, Nairn AC, Aderem A. Tumor necrosis factor alpha modifies agonist-dependent responses in human neutrophils by inducing the synthesis and myristoylation of a specific protein kinase C substrate. Proc Natl Acad Sci U S A 1990; 87:5603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/81\">",
"      Heyworth PG, Badwey JA. Protein phosphorylation associated with the stimulation of neutrophils. Modulation of superoxide production by protein kinase C and calcium. J Bioenerg Biomembr 1990; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/82\">",
"      Torres M, Hall FL, O'Neill K. Stimulation of human neutrophils with formyl-methionyl-leucyl-phenylalanine induces tyrosine phosphorylation and activation of two distinct mitogen-activated protein-kinases. J Immunol 1993; 150:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/83\">",
"      Yan SR, Huang M, Berton G. Signaling by adhesion in human neutrophils: activation of the p72syk tyrosine kinase and formation of protein complexes containing p72syk and Src family kinases in neutrophils spreading over fibrinogen. J Immunol 1997; 158:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/84\">",
"      Lowell CA, Fumagalli L, Berton G. Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. J Cell Biol 1996; 133:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/85\">",
"      Miyabayashi M, Yasui K. Regulation of neutrophil O2- production by neutrophil-endothelial cell interaction via CD11b: its modulation by tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide (LPS). Int J Hematol 1996; 65:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/86\">",
"      Yan SR, Fumagalli L, Berton G. Activation of p58c-fgr and p53/56lyn in adherent human neutrophils: evidence for a role of divalent cations in regulating neutrophil adhesion and protein tyrosine kinase activities. J Inflamm 1995; 45:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/87\">",
"      Berkow RL, Dodson RW, Kraft AS. Human neutrophils contain distinct cytosolic and particulate tyrosine kinase activities: possible role in neutrophil activation. Biochim Biophys Acta 1989; 997:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/88\">",
"      Gaudry M, Caon AC, Gilbert C, et al. Evidence for the involvement of tyrosine kinases in the locomotory responses of human neutrophils. J Leukoc Biol 1992; 51:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/89\">",
"      Gomez-Cambronero J, Huang CK, Bonak VA, et al. Tyrosine phosphorylation in human neutrophil. Biochem Biophys Res Commun 1989; 162:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/90\">",
"      Kusunoki T, Higashi H, Hosoi S, et al. Tyrosine phosphorylation and its possible role in superoxide production by human neutrophils stimulated with FMLP and IgG. Biochem Biophys Res Commun 1992; 183:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/91\">",
"      Cronstein BN, Haines KA, Kolasinski S, Reibman J. Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood 1992; 80:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/92\">",
"      Revan S, Montesinos MC, Naime D, et al. Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J Biol Chem 1996; 271:17114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/93\">",
"      Balazovich KJ, Boxer LA. Extracellular adenosine nucleotides stimulate protein kinase C activity and human neutrophil activation. J Immunol 1990; 144:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/94\">",
"      Clarke TB, Davis KM, Lysenko ES, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/95\">",
"      Hallett MB, Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol Today 1995; 16:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/96\">",
"      Condliffe AM, Chilvers ER, Haslett C, Dransfield I. Priming differentially regulates neutrophil adhesion molecule expression/function. Immunology 1996; 89:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/97\">",
"      Roberts PJ, Williams SL, Linch DC. The regulation of neutrophil phospholipase A2 by granulocyte-macrophage colony-stimulating factor and its role in priming superoxide production. Br J Haematol 1996; 92:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/98\">",
"      Brandolini L, Bertini R, Bizzarri C, et al. IL-1 beta primes IL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium flux. J Leukoc Biol 1996; 59:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/99\">",
"      Kitchen E, Rossi AG, Condliffe AM, et al. Demonstration of reversible priming of human neutrophils using platelet-activating factor. Blood 1996; 88:4330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/100\">",
"      SBARRA AJ, KARNOVSKY ML. The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 1959; 234:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/101\">",
"      Curnutte JT, Babior BM. Chronic granulomatous disease. Adv Hum Genet 1987; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/102\">",
"      Segal AW. The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease. J Clin Invest 1989; 1057:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/103\">",
"      Dinauer MC. The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Crit Rev Clin Lab Sci 1993; 30:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/104\">",
"      Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/105\">",
"      Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002; 416:291.",
"     </a>",
"    </li>",
"    <li>",
"     Klebanoff SJ. Phagocytic cells: Products of metabolism. In: Inflammation: Basic Principles and Clinical Correlates, Gallin JI, Goldstein M, Snyderman R (Eds), Raven Press, 1998. p.391.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/107\">",
"      Malech HL. The role of neutrophils in the immune system: an overview. Methods Mol Biol 2007; 412:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/108\">",
"      Dinauer MC. Disorders of neutrophil function: an overview. Methods Mol Biol 2007; 412:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/109\">",
"      Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/110\">",
"      Mandell GL. Bactericidal activity of aerobic and anaerobic polymorphonuclear neutrophils. Infect Immun 1974; 9:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/111\">",
"      Malawista SE, Montgomery RR, van Blaricom G. Evidence for reactive nitrogen intermediates in killing of staphylococci by human neutrophil cytoplasts. A new microbicidal pathway for polymorphonuclear leukocytes. J Clin Invest 1992; 90:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/112\">",
"      Schmidt HH, Seifert R, B&ouml;hme E. Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4. FEBS Lett 1989; 244:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/113\">",
"      Evans TJ, Buttery LD, Carpenter A, et al. Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria. Proc Natl Acad Sci U S A 1996; 93:9553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/114\">",
"      Bryant JL Jr, Mehta P, Von der Porten A, Mehta JL. Co-purification of 130 kD nitric oxide synthase and a 22 kD link protein from human neutrophils. Biochem Biophys Res Commun 1992; 189:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/115\">",
"      Dembinska-Kiec A, Burchert M, Hartwich J, et al. A neutrophil-derived NO-synthase (NOS) inhibitor. Agents Actions Suppl 1995; 45:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/116\">",
"      Wright CD, Mulsch A, Busse R, Oswald H. Generation of nitric oxide by human neutrophils. Biochem Biophys Res Commun 1989; 28:160:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/117\">",
"      Salvemini D, de Nucci G, Gryglewski RJ, Vane JR. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A 1989; 86:6328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/118\">",
"      Wheeler MA, Smith SD, Garc&iacute;a-Carde&ntilde;a G, et al. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 1997; 99:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/119\">",
"      Kolls J, Xie J, LeBlanc R, et al. Rapid induction of messenger RNA for nitric oxide synthase II in rat neutrophils in vivo by endotoxin and its suppression by prednisolone. Proc Soc Exp Biol Med 1994; 205:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/120\">",
"      Spitznagel JK. Antibiotic proteins of human neutrophils. J Clin Invest 1990; 86:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/121\">",
"      Flannagan RS, Cos&iacute;o G, Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol 2009; 7:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/122\">",
"      Ganz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/123\">",
"      Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A 1990; 87:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/124\">",
"      Shafer WM, Onunka VC, Jannoun M, Huthwaite LW. Molecular mechanism for the antigonococcal action of lysosomal cathepsin G. Mol Microbiol 1990; 4:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/125\">",
"      Campanelli D, Detmers PA, Nathan CF, Gabay JE. Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest 1990; 85:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/126\">",
"      Stinavage P, Martin LE, Spitznagel JK. O antigen and lipid A phosphoryl groups in resistance of Salmonella typhimurium LT-2 to nonoxidative killing in human polymorphonuclear neutrophils. Infect Immun 1989; 57:3894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/127\">",
"      Ellison RT 3rd, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/128\">",
"      Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/129\">",
"      Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/130\">",
"      Menegazzi R, Decleva E, Dri P. Killing by neutrophil extracellular traps: fact or folklore? Blood 2012; 119:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/131\">",
"      Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009; 114:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/132\">",
"      Hakkim A, Hurwitz R, Bianchi M, et al. Protecting against Aspergillus infection in CGD Response. Blood 2009; 114:3498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/31/6650/abstract/133\">",
"      Yost CC, Cody MJ, Harris ES, et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood 2009; 113:6419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8382 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6650=[""].join("\n");
var outline_f6_31_6650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20917272\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERACTIONS BETWEEN MICROBES AND NEUTROPHILS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5933198\">",
"      Pattern recognition receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5933205\">",
"      Apoptotic corpse receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OPSONINS AND OPSONIN RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fc gamma RIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fc gamma RII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fc gamma RI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IgA antibody receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complement receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      C1q receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21345347\">",
"      PHAGOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DEGRANULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SIGNAL TRANSDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Molecular mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Phospholipases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Kinases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adenosine and adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRIMING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MICROBE KILLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Respiratory burst",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Oxidative killing and signalling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nitric oxide pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Non-oxidative microbicidal killing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Defensins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Serprocidins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Bacterial permeability-increasing protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5933783\">",
"      Neutrophil extracellular traps (NETS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20917272\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8382|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/59/8126\" title=\"figure 1\">",
"      Respiratory burst pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/7/42109\" title=\"table 1\">",
"      PMN granule contents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=related_link\">",
"      Determinants of neutrophil movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_31_6651="General criteria for TVH";
var content_f6_31_6651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General guidelines for vaginal access for hysterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Vagina is more than two fingerbreadths at the apex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterus is at least stage 1 with a Valsalva maneuver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Approximate uterine weight less than 280 g (12 weeks gestation size)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pathology confined to the uterus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Leiomyoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adenomyosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abnormal uterine bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cervical cancer in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prolapse",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6651=[""].join("\n");
var outline_f6_31_6651=null;
var title_f6_31_6652="Adjusting cyclophosphamide dose";
var content_f6_31_6652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Algorithm for adjusting oral cyclophosphamide dose for adult patients with renal insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Creatinine clearance* (mL/minute)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cyclophosphamide&nbsp;(CYC) oral dose (mg/kg/day)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt; 100",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-99",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-49",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-24",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt; 15 or dialysis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     CYC: cyclophosphamde; Clcr: creatinine clearance",
"     <br>",
"      Initial 2 mg/kg per day dose and adjustments for renal insufficiency are for daily oral administration of \"low dose\" cyclophosphamide therapy in renal and rheumatic diseases.&nbsp; For approach, other dose adjustments that may be needed, and duration of therapy, refer to topic on General principles of the use of cyclophosphamide in rheumatic and renal disease.",
"     </br>",
"    </p>",
"    <div class=\"footnotes\">",
"     * Can&nbsp;be estimated&nbsp;by using&nbsp;the&nbsp;Cockroft-Gault equation.&nbsp;Clcr&nbsp;= [140-age] * weight (kg)/serum Cr in mg/dL * 72.&nbsp;Multiply result by 0.85 for women. Separate calculators for creatinine clearance using conventional and SI units are available in UpToDate.&nbsp;",
"     <br>",
"      &bull; Usual maximum daily dose is 200 mg.&nbsp; For patients who are overweight or obese, an estimate of ideal or lean body weight is used for estimating Clcr and determining daily CYC weight-based dose.&nbsp;Calculators are available in UpToDate.",
"      <br>",
"       &Delta; CYC is variably dialyzable (~20-50 percent).&nbsp; Dose may require further adjustment depending upon type of dialysis. For intermittent hemodialysis,&nbsp;give dose after session on dialysis days.&nbsp;&nbsp;&nbsp;",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <br>",
"      Adapted&nbsp;with permission from: Rheumatic Disease Clinics of North America 2001. 27(4):863. Copyright &copy; 2001 Elsevier Science.&nbsp; Additional information from de Groot et al. Ann Intern Med 2009. 150(10):670.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6652=[""].join("\n");
var outline_f6_31_6652=null;
var title_f6_31_6653="Duke criteria for IE II";
var content_f6_31_6653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Duke criteria for diagnosis of infective endocarditis - table B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Positive blood cultures for IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Typical microorganism for infective endocarditis from two separate blood cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Viridans streptococci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Streptococcus gallolyticus (formerly S. bovis), including nutritional variant strains (Granulicatella spp and Abiotrophia defectiva)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        HACEK group - Haemophilus spp, Aggregatibacter (formerly Actinobacillus actinomycete comitants), Cardiobacterium hominis, Eikenella spp, and Kingella kingae.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Staphylococcus aureus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Community-acquired enterococci, in the absence of a primary focus;",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Persistently positive blood culture, defined as recovery of a microorganism consistent with IE from:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Blood cultures drawn more than 12 hours apart",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        All of three or a majority of four or more separate blood cultures, with first and last drawn at least one hour apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titer &gt;1:800*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Evidence of endocardial involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Positive echocardiogram for IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TEE recommended in patients with prosthetic valves, rated at least \"possible IE\" by clinical criteria, or complicated IE [paravalvular abscess]; TTE as first test in other patients*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Definition of positive echocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Oscillating intracardiac mass, on valve or supporting structures, or in the path of regurgitant jets, or on implanted material, in the absence of an alternative anatomic explanation",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Abscess",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        New partial dehiscence of prosthetic valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        New valvular regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Increase in or change in preexisting murmur not sufficient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predisposition - predisposing heart condition or intravenous drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever - 38.0&deg;C (100.4&deg;F)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular phenomena - major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunologic phenomena - glomerulonephritis, Osler's nodes, Roth spots, rheumatoid factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microbiologic evidence - positive blood culture but not meeting major criterion as noted previously (excluding single positive cultures for coagulase-negative straphylococci and organisms that do not cause endocarditis)",
"        <strong>",
"         OR",
"        </strong>",
"        serologic evidence of active infection with organism consistent with IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiographic minor criteria eliminated*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modifications from the previous published Duke criteria are noted by the asterisk.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li JS, Sexton DJ, Mick N, et al. Clin Infect Dis 2000; 30:633. Copyright &copy; 2000 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6653=[""].join("\n");
var outline_f6_31_6653=null;
var title_f6_31_6654="Congenital syphilis US";
var content_f6_31_6654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis&mdash;Reported cases among infants by year of birth and rates of primary and secondary syphilis among women, United States, 2002-2011",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 268px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CS: congenital syphilis; P&amp;S: primary and secondary syphilis.",
"    </div>",
"    <div class=\"reference\">",
"     From Sexually Transmitted Disease Surveillance, 2011. Centers for Disease Control and Prevention. Available at:&nbsp;",
"     <a href=\"file://www.cdc.gov/std/stats/\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.cdc.gov/std/stats/",
"     </a>",
"     (Accessed on December 19, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6654=[""].join("\n");
var outline_f6_31_6654=null;
var title_f6_31_6655="Congenital emphysema CT";
var content_f6_31_6655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital lobar emphysema, left upper lobe in adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan demonstrates a hyperexpanded, oligemic left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_31_6655=[""].join("\n");
var outline_f6_31_6655=null;
